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A B S T R A C T
Background
Smoking in pregnancy is a public health problem. When used by non-pregnant smokers, pharmacotherapies (nicotine replacement
therapy (NRT), bupropion and varenicline) are effective for smoking cessation, however, their efficacy and safety in pregnancy remains
unknown. Electronic Nicotine Delivery Systems (ENDS), or e-cigarettes, are becoming widely used but their efficacy and safety when
used for smoking cessation in pregnancy are also unknown.
Objectives
To determine the efficacy and safety of smoking cessation pharmacotherapies (including NRT, varenicline and bupropion), other
medications, or ENDS when used for smoking cessation in pregnancy.
Search methods
We searched the Pregnancy and Childbirth Group’s Trials Register (11 July 2015), checked references of retrieved studies, and contacted
authors.
Selection criteria
Randomised controlled trials (RCTs) conducted in pregnant women with designs that permit the independent effects of any type of
pharmacotherapy or ENDS on smoking cessation to be ascertained were eligible for inclusion.
The following RCT designs are included.
Placebo-RCTs: any form of NRT, other pharmacotherapy, or ENDS, with or without behavioural support/cognitive behaviour therapy
(CBT), or brief advice, compared with an identical placebo and behavioural support of similar intensity.
RCTs providing a comparison between i) any form of NRT, other pharmacotherapy, or ENDS added to behavioural support/CBT, or
brief advice and ii) behavioural support of similar (ideally identical) intensity.
Parallel- or cluster-randomised trials were eligible for inclusion. Quasi-randomised, cross-over and within-participant designs were not,
due to the potential biases associated with these designs.
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Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias and also independently extracted data and cross checked
individual outcomes of this process to ensure accuracy. The primary efficacy outcome was smoking cessation in later pregnancy (in all
but one trial, at or around delivery); safety was assessed by 11 outcomes (principally birth outcomes) that indicated neonatal and infant
well-being; and we also collated data on adherence with trial treatments.
Main results
This review includes a total of nine trials which enrolled 2210 pregnant smokers: eight trials of NRT and one trial of bupropion as
adjuncts to behavioural support/CBT. The risk of bias was generally low across trials with virtually all domains of the ’Risk of bias’
assessment tool being satisfied for the majority of studies. We found no trials investigating varenicline or ENDS. Compared to placebo
and non-placebo controls, there was a difference in smoking rates observed in later pregnancy favouring use of NRT (risk ratio (RR)
1.41, 95% confidence interval (CI) 1.03 to 1.93, eight studies, 2199 women). However, subgroup analysis of placebo-RCTs provided
a lower RR in favour of NRT (RR 1.28, 95% CI 0.99 to 1.66, five studies, 1926 women), whereas within the two non-placebo
RCTs there was a strong positive effect of NRT, (RR 8.51, 95% CI 2.05 to 35.28, three studies, 273 women; P value for random-
effects subgroup interaction test = 0.01). There were no differences between NRT and control groups in rates of miscarriage, stillbirth,
premature birth, birthweight, low birthweight, admissions to neonatal intensive care, caesarean section, congenital abnormalities or
neonatal death. Compared to placebo group infants, at two years of age, infants born to women who had been randomised to NRT
had higher rates of ’survival without developmental impairment’ (one trial). Generally, adherence with trial NRT regimens was low.
Non-serious side effects observed with NRT included headache, nausea and local reactions (e.g. skin irritation from patches or foul
taste from gum), but these data could not be pooled.
Authors’ conclusions
NRT used in pregnancy for smoking cessation increases smoking cessation rates measured in late pregnancy by approximately 40%.
There is evidence, suggesting that when potentially-biased, non-placebo RCTs are excluded from analyses, NRT is no more effective
than placebo. There is no evidence that NRT used for smoking cessation in pregnancy has either positive or negative impacts on
birth outcomes. However, evidence from the only trial to have followed up infants after birth, suggests use of NRT promotes healthy
developmental outcomes in infants. Further research evidence on NRT efficacy and safety is needed, ideally from placebo-controlled
RCTs which achieve higher adherence rates and which monitor infants’ outcomes into childhood. Accruing data suggests that it would
be ethical for future RCTs to investigate higher doses of NRT than those tested in the included studies.
P L A I N L A N G U A G E S U M M A R Y
Drug treatments for stopping smoking in pregnancy
Smoking during pregnancy harms women and infants. Women who continue to smoke during pregnancy generally are poorer and
more poorly educated and are more likely to have no partner or have a partner who smokes.
Medications to help stop smoking include nicotine replacement therapy (NRT), bupropion and varenicline. E-cigarettes contain
nicotine and are used by some smokers to help avoid smoking. The safety and effectiveness of smoking cessation drugs and e-cigarettes
is not known. This updated review sought evidence for the efficacy and safety of any smoking cessation drugs or e-cigarettes when
these are used in pregnancy and found nine randomised studies that enrolled a total of 2210 women. Studies tested NRT used with
behavioural support (counselling) apart from a small bupropion trial which enrolled only 11 women. Together, these showed borderline
evidence to suggest that NRT combined with behavioural support, might help women to stop smoking in later pregnancy. However,
when just the higher-quality, placebo-controlled trials were analysed, NRT was found to be no more effective than a placebo.
There was insufficient evidence to conclude whether or not NRT had either positive or negative impacts on rates of miscarriage,
stillbirth, preterm birth (less than 37 weeks’), low birthweight (less than 2500 g), admissions of babies to neonatal intensive care or
neonatal deaths or whether this affected mean birthweights amongst infants. However, in one trial in which infants were followed to
two years of age, those born to women who had been randomised to NRT were more likely to have healthy development.
Side effects observed with NRT included headache, nausea and local reactions (e.g. skin irritation from patches or foul taste from gum).
Studies that reported adherence to medication found that this was generally low and the majority of participants did not use a large
proportion of the NRT that was offered or prescribed to them.
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More research evidence is needed; in particular, placebo-controlled trials that test higher doses of NRT, encourage high adherence rates
and follow infants into childhood are now warranted.
B A C K G R O U N D
Description of the condition
Risks associated with smoking in pregnancy
Tobacco smoking during pregnancy is the most important, po-
tentially-preventable cause of a range of adverse pregnancy out-
comes, including placental abruption, miscarriage, preterm birth
(less than 37 weeks’ gestation) and low birthweight (less than 2500
g) (Hammoud 2005; Salihu 2007; US DHHS 2004). Cigarette
smoking causes intrauterine growth restriction, probably through
a reduction in the supply of oxygen and other essential fetal nutri-
ents (Crawford 2008); it is also associated with poorer fetal neuro-
development (Herrmann 2008). Preterm birth is the leading cause
of neonatal mortality (Hammoud 2005; Kramer 1987) and mor-
bidity, with up to half of all paediatric neurodevelopmental prob-
lems ascribed to preterm birth (Green 2005). Low birthweight is
a surrogate measure of the harmful impact of tobacco smoking
on fetal development, and there is growing evidence of the asso-
ciation between low birthweight and adult morbidities, includ-
ing coronary heart disease, type 2 diabetes mellitus, and adiposity
(Gluckman 2008).
Tobacco smoking also has many long-term health impacts for
women and their children, and is a major risk factor for six of the
eight leading causes of death globally (WHO 2008).
Tobacco addiction is caused by the nicotine in tobacco, which pro-
duces a cascade of actions, including release of “pleasure enhanc-
ing” dopamine, which strengthens associations of positive feelings
with smoking behaviour and appears to be involved in all addictive
behaviours (Schmidt 2004).
Epidemiology of smoking in pregnancy
Tobacco smoking is associated with low socioeconomic status and
has been cited as one of the principal causes of health inequality
between rich and poor (Wanless 2004).
In high-income countries, such as the United States (US), Den-
mark and Sweden, the prevalence of smoking in pregnancy has de-
clined from between 20% and 35% in the 1980s to between 10%
to 20% in 2000s (Al-Sahab 2010; Cnattingius 2004; Dixon 2009;
Giovino 2007; Tappin 2010; Tong 2009; US DHHS 2004), and
below 10% by 2010 (Lanting 2012). However, the decline has
not been consistent across all sectors of society, with lower rates
of decline in lower socioeconomic groups (Graham 2010; Lanting
2012; Pickett 2009; US DHHS 2004). There are marked socioe-
conomic differences between women who continue to smoke in
pregnancy and those who do not. Compared to women in ap-
propriate reference groups, those who continue to smoke in preg-
nancy generally have lower incomes; higher parity; lower levels of
social support; more limited education; are younger; receive pub-
licly-funded or deficient maternity care; are without a partner or
with a partner who smokes and are more likely to feel criticised
by society (Ebert 2007; Frost 1994; Graham 1976; Graham 1996;
Schneider 2008; Tappin 1996; US DHHS 2004). There is a sig-
nificantly higher prevalence of smoking in pregnancy in several in-
digenous and ethnicminority groups, which is in accord with their
social and material deprivation (Chan 2001; Hunt 2003; Kaplan
1997; USDHHS 2004;Wiemann 1994). Despite the high preva-
lence, there is a paucity of evidence-based literature into interven-
tions to reduce antenatal smoking in indigenous groups (Gilligan
2007). In somemigrant groups, cultural differencesmay cut across
this social gradient. Women who are migrants or refugees to the
United Kingdom, Northern Europe, North America or Australia
and who originate from South East Asia retain a lower prevalence
of smoking, despite major social disadvantage (Bush 2003; Potter
1996; Small 2000). However, second generation migrant women
are more likely to smoke during pregnancy (Troe 2008). In the
US, AfricanAmerican,Hispanic, and Pacific-Islander womenhave
a lower prevalence of smoking in pregnancy than white women
(Andreski 1995; US DHHS 2004; Wiemann 1994).
The global tobacco smoking epidemic is shifting from high-in-
come countries to low- and middle-income ones, with predic-
tions that 80% of the eight million annual tobacco-related deaths
will be occurring in low-middle income countries within 30 years
(Oncken 2010). World wide, the prevalence of tobacco smoking
and smokeless tobacco use among women is increasing, not de-
creasing, and is expected to rise to 20% by 2025 (Oncken 2010;
Richmond 2003; Samet 2001). The World Health Organization
(WHO) has identified this rise of tobacco use in young females in
low-income, high-population countries as one of the most omi-
nous developments of the tobacco epidemic (WHO 2008). Na-
tional rates of smoking in pregnancy appear to be associated with
economic development; for example, in Poland the prevalence is
estimated at 30% (Polanska 2005), while the prevalence in coun-
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tries such as the Democratic Republic of Congo is still very low
(Richmond 2003). However, given the aggressive nature of to-
bacco marketing, there is concern that prevalence of smoking
in pregnancy will increase with economic development (WHO
2008), with subsequent health impacts on countries with already
high disease burdens and limited resources to provide health care
and in particular, neonatal care (Cnattingius 2004).
In addition to the socioeconomic factors associated with contin-
ued smoking, there is a growing understanding of psychologi-
cal associations, especially depression and stress (Aveyard 2007;
Blalock 2005; Crittenden, 2007).Depressedwomen are up to four
times more likely to smoke during pregnancy than non depressed
women (Blalock 2005), but there is limited information available
about the effects of smoking and interventions in pregnant women
with psychological symptoms as they are often excluded from tri-
als (Blalock 2005). Two reviews in the general population (Stead
2013; Tsoi 2013), and several trials of smoking cessation inter-
ventions conducted in pregnant women, report higher levels of
stress and depression among women who continue to smoke dur-
ing pregnancy (Aveyard 2007; Blalock 2005; Crittenden, 2007).
A higher proportion of women stop smoking during pregnancy
than at other times in their lives. Up to 45% of women who smoke
before pregnancy “spontaneously quit” or stop before their first
antenatal visit (Quinn 1991; The NHS Information Centre 2011;
Woodby 1999); this ’quit rate’ is substantially higher than reported
in the general population (McBride 2003). ’Spontaneous quitters’
usually smoke less and are more likely to have temporarily stopped
smoking previously; have a non-smoking partner; have more sup-
port and encouragement at home for quitting; have stronger be-
liefs about the dangers of smoking, or be less seriously addicted
(Baric 1977; Ryan 1980). Consequently, women who are eligible
for smoking cessation assistance in pregnancy are likely to find
it more difficult to quit than those in other populations. How-
ever, only a third of women who stop smoking spontaneously re-
main abstinent after one year (CDCP 2002). McBride 2003 hy-
pothesises that pregnancy may be a “teachable moment” at which
women perceive increased risk from smoking and become more
motivated to attempt smoking cessation. These factors highlight
some of the major differences between the non-pregnant popula-
tion included in trials of pharmacotherapy for smoking cessation
and pregnant women who continue to smoke after they become
pregnant (Oncken 2009b).
Smoking cessation in pregnancy
In addition to acknowledgedbenefits formaternal health, stopping
smoking in pregnancy has positive impacts on infants’ outcomes.
Research studies show that smoking cessation interventions deliv-
ered in pregnancy reduce the prevalences of low birthweight and
preterm births, both of which are accompanied by substantial in-
fant morbidity and mortality (Chamberlain 2013: Lumley 2009).
Similar findings have been observed in women who stop smoking
after receiving standard antenatal care, suggesting that trial find-
ings are probably generalisable to all women who stop smoking in
early pregnancy whether or not they participate in research studies
(McCowan 2009).
Some non-pharmacological (psychosocial) interventions are effec-
tive in reducing the proportion of women who smoke during preg-
nancy and the evidence for these can be obtained from an asso-
ciated review (Chamberlain 2013), and a previous version of this
review (Lumley 2009). For example, compared to usual care, a
range of counselling or behavioural support interventions, were
demonstrated as effective (risk ratio 1.44, 95% confidence interval
1.19 to 1.75, 27 studies) (Chamberlain 2013). Financial incen-
tives also appear to be effective, but this finding was based on only
four small US trials that compared incentives to a range of con-
trol conditions (Chamberlain 2013); incentives used in addition
to routine care in other countries may have different effects.
Before reviews for pharmacological (Coleman 2012) and psy-
chosocial (Chamberlain 2013) interventions against smoking in
pregnancy were divided, the overall review of pregnancy cessa-
tion interventions classifiedmultimodal intervention strategies for
combining in meta-analyses by their predominant intervention
strategy (Lumley 2009).This analysis approach permitted synthe-
sis of multi-component interventions and the review’s meta-anal-
ysis for studies, which were categorised as having nicotine replace-
ment therapy (NRT) as the predominant intervention strategy in-
cluded a quasi-randomised controlled trial (RCT) that compared
NRT with intensive behavioural smoking cessation support (an
effective cessation treatment) with normal antenatal care only (i.e.
no behavioural support) (Hegaard 2003). Consequently, this anal-
ysis (Lumley 2009), investigated the effectiveness of multi-com-
ponent intervention strategies which included NRT rather than
the efficacy of NRT for cessation in pregnancy. Splitting reviews
was intended to alter this situation, such that multi-modal inter-
ventions are included in the psychosocial review, and this review
provides evidence on the independent efficacy and safety effects
of pharmacological interventions in pregnancy.
Description of the intervention
Any pharmacological intervention, including electronic nicotine
delivery systems (ENDS, (e-cigarettes)), used by pregnant women
for the purposes of stopping smoking, with or without additional
behavioural support or cognitive behaviour therapy (CBT).
How the intervention might work
One would expect NRT, bupropion and varenicline, which are all
frequently-used, effective, pharmaceutical smoking cessation in-
terventions to have the same mechanisms of action in pregnant
women as they do innon-pregnant smokers.NRTworks by substi-
tuting ’clean’ nicotine inmedicinal forms (e.g. transdermal patches
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or lozenges) for nicotine which would have been inhaled with to-
bacco smoke. The NRT dose is gradually reduced so that smokers’
intake of medicinal nicotine decreases until they can comfortably
stop NRT without experiencing excessive withdrawal symptoms.
Additionally, when nicotine is provided via NRT, the user avoids
roughly 4000 other toxins that are inhaled with nicotine in to-
bacco smoke (Stedman 1968); consequently medicinal nicotine
is likely to be safer than tobacco smoke nicotine. Bupropion is
an antidepressant which has both dopaminergic and adrenergic
actions (Ascher 1995; Cooper 1994), whilst also appearing to an-
tagonise the nicotinic acetyl cholinergic receptor (Slemmer 2000);
its mechanism of action for smoking cessation remains uncertain.
Varenicline is an alpha 4 beta 2 nicotinic acetylcholine receptor
partial agonist. It attaches to the nicotinic acetylcholine receptor
and is believed tomimic the pleasurable dopaminergic (dopamine-
releasing) effect of nicotine. Varenicline binds more easily to re-
ceptors than nicotine, so when abstinent smokers use this drug, re-
ceptors become blocked with varenicline. Should varenicline users
choose to smoke, varenicline then prevents nicotine from attach-
ing to receptors so this cannot cause any pleasurable effects for
smokers (Coe 2005). Consequently, smoking whilst using vareni-
cline is less enjoyable and attractive for smokers who also expe-
rience fewer cravings or withdrawal symptoms and so, are better
able to remain abstinent.
The metabolism of many drugs, including of nicotine, is increased
in pregnancy and any medications that are metabolised more
swiftly can become less effective at standard doses. Cotinine, the
primary metabolite of nicotine, is metabolised muchmore quickly
in pregnancy (Dempsey 2001), so nicotine replacement therapies
used by pregnant women would be expected to generate lower
blood levels of nicotine and these might not adequately substitute
for nicotine received from smoking. Consequently, one might ex-
pect NRT to be less effective for smoking cessation in pregnancy
than it is when used outside of pregnancy. The metabolism of
bupropion and varenicline is not known to be altered in preg-
nancy.
A caveat to the use of pharmaceutical treatments for smoking ces-
sation in pregnancy is that of potential fetal harm caused by their
use. There are insufficient studies investigating the fetal impacts
of either bupropion or varenicline use in pregnancy to draw any
conclusions about the safety of using either. There are, however,
more studies demonstrating the effects of nicotine on the fetus
and these suggest that nicotine is a fetal toxin (Dempsey 2001).
Also, nicotine crosses the placenta and accumulates in the develop-
ing fetus (Maritz 2009; Rore 2008) causing concerns about both
short-term effects on newborns (Gaither 2009) and longer-term
impacts on infants (Bruin 2010). However, as tobacco smoke con-
tains nicotine plus many other toxins and NRT delivers nicotine
alone, there is a consensus amongst experts that maternal use of
NRT in pregnancy should be safer for the fetus than continued
smoking (Benowitz 2000); though currently, there is insufficient
research evidence to support this view. The first version of this
review investigated the impact of pharmacological interventions
on birth outcomes; however, as at least one trial known to the
authorship team is known to be following up infants after use of
pharmacological interventions in pregnancy, this review also seeks
information on childhood outcomes after use of these interven-
tions in pregnancy.
Since the last version of this review was published, ENDS or e-
cigarettes have been used with increasing frequency; these are de-
vices that do not burn tobacco leaves, instead by heating a solu-
tion that contains nicotine, a nicotine-containing aerosol that the
user inhales is released (Cobb 2010). The awareness and use of
ENDS is increasing (Regan 2013), with over 400 brands now on
the market (Zhu 2014), and 2.1 million current users in the UK
in 2014 (Action on Smoking and Health 2014). There is vigor-
ous debate about the public health impact, regulation, and role of
ENDS in smoking cessation (Auf 2014; Benowitz 2014; Bialous
2014;Doyle 2014;Hitchman 2014). A recent reviewby theWHO
(WHO 2013), which is also controversial (McNeill 2014), sug-
gests there is a lack of evidence for three main concerns regard-
ing ENDS, including: health risks to users and non-users, efficacy
in smoking cessation, and interference with tobacco control ef-
forts. In terms of health risks, ENDS contain less toxic substances
(such as tar and carbon monoxide) than conventional cigarettes
(Etter 2011), but data are limited (Goniewicz 2014; Orr 2014),
and ENDS do contain other by-products from metals, plastics,
rubbers, ceramics, fibres, and foams (Brown 2014b). The WHO
state there is sufficient evidence to caution pregnant women about
the use of ENDS due to concerns about the risks of exposure on
fetal and child brain development (Dwyer 2009;WHO2013), in-
cluding from flavourings (Bahl 2012), and concludes ENDS pose
potential threats to adolescents and fetuses, but this is less than
conventional cigarettes. In terms of smoking cessation efficacy,
there has been one placebo-RCT investigating ENDS, conducted
in non-pregnant smokers; this found no significant difference
in smoking cessation rates between ENDS and placebo-ENDS
groups (Bullen 2013). A non-placebo controlled trial showed some
effect on smoking cessation (Caponnetto 2013), and there are
mixed results fromuncontrolled studies (again, all in non-pregnant
smokers) (Adkison 2013; Brown 2014a; Grana 2014a; Vickerman
2013), with systematic reviews concluding there are limited data
and evidence of effectiveness for smoking cessation (Drummond
2014; Farsalinos 2014; Franck 2014; Grana 2014; Harrell 2014).
We are not aware of any studies investigating ENDS use in preg-
nant smokers.
Why it is important to do this review
Guidelines from many countries recommend that NRT can be
offered for smoking cessation in pregnancy to heavy smokers
who have been unable to quit smoking using behavioural or psy-
chosocial methods (Murin 2011; National Institute for Clinical
Excellence 2002);Oncken2009b;Osadchy 2009; Rore 2008).We
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have been unable to find any clinical guidelines which recommend
using bupropion and varenicline in pregnancy. These treatments
are not recommended in pregnancy as there is very limited evi-
dence for their safety (Rore 2008); also, using them would involve
fetal exposure to potential additional toxins (i.e. possibly within
these drugs) that could be entirely avoided. In most high-income
countries (e.g. Canada, US, Australia, New Zealand), guidelines
recommend that pregnant women are offered intermittent NRT-
delivery formulations (e.g. gum, lozenges, spray - classified as cat-
egory C drugs in pregnancy), rather than continuous ones (e.g.
patches - classified as category D) (Bruin 2010). The theoretical
rationale for this is that the overall dose of nicotine delivered by
intermittent formulations may be lower than that delivered by
continuous ones (Oncken 2009a), and that the peaks in blood
nicotine concentrations are more extreme, mimicking the action
of smoking. However, some experts recommend patches as the
lower peak nicotine levels associated with these may induce fewer
side effects, such as gum and throat irritation (Oncken 2009b;
Rore 2008).
Consensus-based recommendations about using NRT for smok-
ing cessation in pregnancy are underpinned by a belief that medic-
inal NRT is safer than smoking. (Benowitz 2000) However, to
date, individual trials have had inconsistent findings (Pollak 2007;
Wisborg 2000), and there is no conclusive evidence that NRT
is either effective or safe in pregnancy (Coleman 2011; Coleman
2012). There are also reports of low adherence to NRT regimens;
low adherence could reduce efficacy and suggests the acceptabil-
ity of NRT use in pregnancy may be limited. (Coleman 2011;
Coleman 2012)
Given that NRT appears to be widely accepted for cautious use
in pregnancy, a Cochrane review investigating the efficacy and
safety of this clinical practice and also the potential for other drugs
to be safely used is warranted. Additionally, although ENDS (e-
cigarettes) are not recognised or regulated as a smoking cessation
treatment, trials investigating their efficacy are underway in non-
pregnant populations, hence we have included a search for relevant
trials in pregnant smokers as part of this review. A robust synthesis
of research evidence on the use of pharmacological treatments for
cessation in pregnancy will help advance clinical practice in an
area of substantial clinical need.
O B J E C T I V E S
1. To determine whether or not nicotine replacement therapy,
bupropion, varenicline, other drug treatments or electronic
nicotine delivery systems (ENDS) (e-cigarettes) used in
pregnancy, are effective for smoking cessation in later pregnancy
and after childbirth.
2. To determine whether or not nicotine replacement therapy,
bupropion, varenicline, other drug treatments or ENDS used in
pregnancy, affect infants’ mean birthweight or preterm birth.
3. To determine whether or not nicotine replacement therapy,
bupropion, varenicline, other drug treatments or ENDS used in
pregnancy, affect rates of caesarean section or adverse perinatal
outcomes.
4. To determine whether or not nicotine replacement therapy,
bupropion, varenicline, other drug treatments or ENDS used in
pregnancy, affect post-perinatal infant outcomes.
5. To document levels of i) adherence to treatment regimens
and ii) minor adverse events in trials investigating the efficacy
pharmacotherapies or ENDS for smoking cessation in pregnancy.
6. To document any reported long-term effects of smoking
cessation pharmacotherapies or ENDS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Trials that investigate the efficacy of pharmacotherapies for smok-
ing cessation in pregnancy are included.
Trials in pregnant women investigating the efficacy of either phar-
macotherapies or of electronic nicotine delivery systems (ENDS)
for smoking cessation are included.
Randomised controlled trials (RCTs) with designs that permit the
independent effects of any type of pharmacotherapy or ENDS
on smoking cessation will be included. Trials must provide very
similar (ideally identical) levels of behavioural support or cogni-
tive behaviour therapy (CBT) to participants in active drug and
comparator trial arms; behavioural support is effective for smok-
ing cessation in pregnancy (Chamberlain 2013), and differences
in its provision would be expected to affect cessation and birth
outcomes, potentially rendering findings difficult to interpret.
The following RCT designs are acceptable.
1. Placebo-RCTs: any form of NRT or other
pharmacotherapy or ENDS, with or without behavioural
support/CBT, or brief advice, compared with an identical
placebo plus behavioural support of similar intensity.
2. RCTs providing a comparison between i) any form of NRT
or other pharmacotherapy or ENDS plus behavioural support/
CBT or brief advice and, ii) behavioural support of similar
(ideally identical) intensity.
Parallel- or cluster-randomised design trials are eligible for inclu-
sion. However, quasi-randomised, cross-over and within-partici-
pant designs are not eligible for inclusion due to the potential bi-
ases associated with these designs.
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Types of participants
Women who are pregnant and who also smoke.
Types of interventions
Pharmacological treatments aimed at promoting smoking cessa-
tion including, but not exclusive to, treatments that have been
proven effective in non-pregnant adults (e.g. NRT (Stead 2012),
bupropion (Hughes 2014), varenicline (Cahill 2012); and ENDS
used to promote smoking cessation.
Types of outcome measures
Outcomes include measures of efficacy, safety and adherence with
treatments. Measures include maternal and infant outcomes as-
sessed in pregnancy, around childbirth and up to two years after-
wards.
Primary outcomes
Self-reported abstinence from smoking in later pregnancy taken
at the latest point prior to birth at which this is measured and,
where available, validated using biochemicalmeanswith cut points
derived by expert consensus: 8 ppm (parts per million) for ex-
haled carbon monoxide (SRNT2002) and 10 ng/mL for saliva co-
tinine (SRNT2002). When validated abstinence data were avail-
able, these were used in preference to self-report. Where available,
we also used prolonged, continuous abstinence measures timed
from a quit date set in early pregnancy and which allowed tem-
porary lapses to smoking as per the Russell Criteria for outcome
measurement in cessation studies (West 2005). However, point
prevalence abstinence measures were substituted for these as re-
quired.
Secondary outcomes
1. Abstinence from smoking after childbirth
2. Safety
i) Miscarriage/spontaneous abortion
ii) Stillbirth
iii) Mean unadjusted birthweight
iv) Low birthweight (less than 2500 g)
v) Preterm birth (less than 37 weeks’ gestation)
vi) Neonatal intensive care unit admissions.
vii) Neonatal death
viii) Caesarean section
ix) Maternal hypertension
x) Infant respiratory symptoms
xi) Infant development
3. Adherence data
4. Non-serious side effects (serious adverse event data
contributed to ‘safety’ outcomes, above)
5. Any reported long-terms effects of smoking cessation
pharmacotherapies
NB: A specific search was not made for 3 and 4 above but, if
present, these data were extracted from included studies and de-
scribed qualitatively.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (11 July
2015).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Searching other resources
We checked relevant, cited studies while reviewing the trial reports
and also from any reviews identified. We contacted trial authors,
as necessary, to locate additional unpublished data.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Coleman 2012.
For this update, the following methods were used to assess the
nine reports that were identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
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Selection of studies
This describes identification of papers published since the first
version of this review and added to those included in this earlier
review (see Other published versions of this review). Two review
authors, Tim Coleman (TC) and Catherine Chamberlain (CC),
working independently, inspected the search results. Separate lists
of titles and abstracts that were potentially suitable for inclusion
weremade and any disagreements were resolved by discussion with
Sue Cooper (SC)
Data extraction and management
We designed a data extraction form based on that used by Lumley
2009 and, for eligible studies, three review authors (TC, Jo
Leonardi-Bee, JLB and Mary-Ann Davey, MAD) used this to ex-
tract data from all included trials; the third included paper was
authored by TC and SC, so Catherine Chamberlain (CC) and JLB
conducted data extraction for this. Extracted data were compared,
with any discrepancies being resolved through discussion or, if re-
quired, by consulting another author (SC). TC entered data into
Review Manager software (RevMan 2014), double checking this
for accuracy. Studies that could only be excluded after reading the
full text are listed in the Characteristics of excluded studies table.
When information regarding any of the above was unclear, we
contacted authors of the reports to provide further details.
Assessment of risk of bias in included studies
TC and SC independently assessed risk of bias for all studies which
they had not authored, using criteria adapted from those in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). Criteria were adapted such that the sixth criterion for ’other
sources of bias’ addressed biochemical validation of smoking status
at the primary outcome point of included trials (further details
below). Any disagreements were resolved by discussion without
the need to involve a third review author. An identical process was
followed by two other authors, CC and JL-B, for the two studies
that SC and TC had authored (Coleman 2012; Cooper 2014).
For all studies we assessed the following quality domains.
(1) Random sequence generation (checking for possible
selection bias)
We determined whether the method used to generate the alloca-
tion sequence was sufficiently described to allow an assessment of
whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
Wedetermined themethodused to conceal the allocation sequence
and whether intervention allocation could have been foreseen in
advance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3) Blinding (checking for possible performance bias)
We determined the methods used, if any, to blind study partici-
pants and personnel from knowledge of which intervention a par-
ticipant received. In the previous version of this review, we cate-
gorised studies that used placebo to be at low risk of bias and those
which used a behavioural control only as at high risk of bias. Us-
ing this categorisation of bias, findings with respect to efficacy of
nicotine replacement therapy were different for placebo (low bias)
and non-placebo (at risk of bias) randomised controlled trials, so
we have maintained the same classification for this update. In the
’Risk of bias’ table we note whether or not participants, personnel
or outcome assessors were blinded to outcome assessment.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We determined for the primary outcome (i.e. smoking cessation),
the completeness of data including attrition and exclusions from
the analysis and whether an intention-to-treat analysis (i.e. report-
ing trial arm cessation rates amongst all those who were originally
randomised to that arm) was reported. We assessed whether attri-
tion and exclusions were reported, the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes.
(5) Selective reporting bias
We determined the possibility of selective outcome reporting bias
and assessed methods as:
• low risk of bias (where it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
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• unclear risk of bias.
(6) Biochemical validation of smoking status at primary
outcome point (checking for detection bias)
We determined, the timing of, and methods used to ascertain
smoking status at the primary outcome point. In pregnancy, bio-
chemical validation is considered important to ensure that study
participants are not biased towards reporting smoking cessation
and we used cut points derived by expert consensus: 8 ppm where
exhaled carbon monoxide is used for validation and 10 ng/mL for
saliva cotinine.
(7) Other risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook
(Higgins 2011). As drug efficacy was being assessed, allocation
concealment and blinding were considered particularly important
for differentiating between placebo and active drug effects. Also,
given that smoking in pregnancy attracts stigma in many societies,
biochemical validation of smoking status was considered impor-
tant as a means of minimising any ’desirable’ response bias from
trial participants. We assessed the likely magnitude and direction
of the bias and whether this was likely to impact on the findings.
Measures of treatment effect
Dichotomous data
For dichotomous data (all outcomes except mean birthweight),
results are presented as summary risk ratios with 95% confidence
intervals.
Continuous data
For mean birthweight (continuous data), we present themean dif-
ference in mean birthweight between trials’ control and interven-
tion group infants with 95% confidence intervals.
Unit of analysis issues
Multiple pregnancies
The unit of analysis for smoking cessation was the trial participant,
as clustering of babies within mothers is not relevant to this out-
come. For all other outcomes, analyses were conducted amongst
singleton births only; this approach was taken because adverse
pregnancy events/outcomes, adverse infant birth outcomes and
poorer infant development are strongly associated with multiple
pregnancy. Hence, analysing multiple and singleton pregnancies
together for these outcomes could render review findings difficult
to interpret. There were not sufficient outcome data frommultiple
births for these to be analysed separately.
Cluster-randomised trials
This study design is eligible for inclusion, however no cluster-ran-
domised trials were identified in this update. In future updates, we
will include cluster-randomised trials in the analyses along with
individually-randomised trials. We will adjust their sample sizes
or standard errors using the methods described in the Handbook
[Section 16.3.4 or 16.3.6] using an estimate of the intracluster cor-
relation co-efficient (ICC) derived from the trial (if possible), from
a similar trial or from a study of a similar population. If we use
ICCs from other sources, we will report this and conduct sensi-
tivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
This is not an eligible study design for this review.
Dealing with missing data
For smoking outcomes we noted levels of attrition and the de-
nominator was the number of women randomised; at all outcome
points, participants whose smoking status was unknown were as-
sumed to be smoking (intention-to-treat analysis).
For other outcomes, the following denominators were used.
a) For pre-birth outcomes, spontaneous abortion/miscarriage and
stillbirth, the denominator used was the number of women ran-
domised with viable singleton pregnancies at the time of randomi-
sation. Where terminations occurred after randomisation, termi-
nated fetuses were excluded from the denominator if terminations
were performed on a presumed viable fetus for non-medical rea-
sons. Similarly, pregnancies that were documented as non-viable at
the point of randomisation were also excluded from this denomi-
nator (e.g.missed abortion).Where terminationswere undertaken
for medical reasons and which were judged incompatible with life,
these cases were included in denominators and also within numer-
ators; they were counted as miscarriages, if performed before 24
weeks and as stillbirths if conducted after this time point.
b) For mean unadjusted birthweight (i.e. the only birth outcomes
measured on a continuous scale), the denominator used was the
number of singleton births for which this outcome was recorded.
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c) For dichotomous birth outcomes: e.g. low birthweight; preterm
birth; neonatal intensive care admissions and neonatal death, the
denominator used was the number of live births from singleton
pregnancies.
d) For infant outcomes: the number of live births was used.
For selected secondary outcomes and where this was appropriate
and feasible, we conducted sensitivity analyses to investigate the
impact of missing data on pooled treatment effect estimates.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis (caveats outlined above); we attempted
to include all participants randomised to each group in analyses,
and all participants were analysed in the group to which they were
allocated regardless of whether or not they received the allocated
intervention.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the I² test and regarded heterogeneity as substantial and, hence
worthy of further investigation (see below), if the I² was greater
than 50%, and regarded it as considerable and incompatible with
presenting as pooled analyses if the I² was more than 75%. Where
it was not possible to perform a meta-analysis due to considerable
levels of heterogeneity (I² greater than 75%), we summarised the
data for each trial and conducted subgroup analyses (see below)
to explore reasons for heterogeneity.
Assessment of reporting biases
As there were less than 10 studies in all meta-analyses, we did
not draw funnel plots to assess the potential for reporting bias. In
future updates of this review, if there are 10 ormore studies, wewill
investigate reporting biases (such as publication bias) using funnel
plots.Wewill assess funnel plot asymmetry visually if asymmetry is
suggested by a visual assessment, and we will perform exploratory
analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014). We suspected that the level of heterogene-
ity between the trials due to clinical and methodological diversity
would be sufficient to suggest that the treatment effects may dif-
fer across the trials, therefore, we elected to use a random-effects
model for combining trials together in themeta-analysis; the over-
all treatment effect from this kind of meta-analysis represents an
average. Thus, for studies with a similar type of active intervention,
we performed meta-analysis to calculate a weighted treatment ef-
fect across studies, using a random-effects meta-analysis. Where it
was not possible to perform a meta-analysis due to considerable
levels of heterogeneity (I² greater than 75%), the data were sum-
marised for each trial. In future updates of the review, where suffi-
cient numbers of studies are included in themeta-analyses, wemay
consider performing random-effects meta-regressions analyses to
further explore reasons for heterogeneity or to analyse adherence
data. A caveat to using this method for adherence data is that there
is currently no standard method for reporting adherence; however,
for meta-regression to be undertaken, studies must report adher-
ence data similarly.
Subgroup analysis and investigation of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using I²
and additionally reported Tau². An exploration of heterogeneity
was performed for primary and secondary outcomes where the
I² was greater than 50%. Where substantial heterogeneity was
detected between studies, an overall pooled result was presented;
however, readers are advised to use caution in interpreting results
due to the presence of heterogeneity.
For smoking cessation outcomes, we planned one subgroup anal-
ysis comparing placebo-RCTs with RCTs that did not use a
placebo (i.e. non-placebo controlled RCTs). For secondary out-
comes, where the I² was greater than 50%, indicating substantial
heterogeneity, we also performed this subgroup analysis as an ex-
ploration of heterogeneity. It was not, however, conducted rou-
tinely for all secondary outcomes.
We assessed differences between subgroups statistically using ran-
dom-effects subgroup interaction tests, and present the P values
from the tests.
Sensitivity analysis
Depending on the availability of data, we planned two sensitivity
analyses using smoking cessation outcomes.
1. Including only trials with biochemical validation of
smoking status.
2. Excluding any trials which reported substantially lower
adherence with treatment than others (NB: we anticipated
defining ’low adherence’ after included studies had been
identified, because there was no normative data on adherence
with NRT in trials in pregnancy).
Neither of these analyses were undertaken in the current review
(explanations follow in results section); data permitting, they will
be undertaken in future review updates.
R E S U L T S
Description of studies
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Results of the search
Searches conducted since the last version of this review identified
10 trial reports for potential inclusion. Three were conference re-
ports describing an already-included study (Coleman 2012), three
are ongoing studies (see below). No studies were excluded.
The four remaining papers were obtained and these were judged to
meet the inclusion criteria and are included in this update (Berlin
2014; El-Mohandes 2013; Stotts 2015). A further paper, which
had not been published, and so was not identified by searches,
was also deemed relevant (Cooper 2014). This manuscript was
authored by members of the review team and reported two-year
follow-up for a study included in the previous version of this review
(Coleman 2012). Six trials included in previous versions of this
review are also included in this update (Coleman 2012; Hotham
2006; Kapur 2001; Oncken 2008; Pollak 2007; Wisborg 2000).
This updated review, therefore, includes nine trials (27 reports). It
contains data from three additional trials published since the pre-
vious version (Berlin 2014; El-Mohandes 2013; Stotts 2015), and
involves 2210 pregnant smokers. We added three newly identified
reports of Coleman 2012, and also one paper reporting two-year
outcomes (Cooper 2014) for this already included study.
Ongoing studies
There are five ongoing studies. A previously-identified ongoing
study has now stoppeddue to recruitment problems (Koren 2008),
and progress with another was uncertain as the relevant trial reg-
istry entry had not been updated for over two years; however,
this is not an RCT and would not be included in this review
(Oncken 2009c). Other ongoing studies include a nicotine re-
placement therapy (NRT) trial (Oncken 2012), and two trials of
bupropion (Hankins 2011; Kranzler 2014). For further details,see
Characteristics of ongoing studies.
Included studies
Interventions
Eight studies investigated the efficacy of different forms of NRT;
one study investigated bupropion (Stotts 2015), and no trials
investigated other smoking cessation pharmacotherapies or elec-
tronic nicotine delivery systems (ENDS).
Nicotine replacement therapy (NRT) studies
All studies investigated the efficacy of NRT provided with be-
havioural support and either compared this with behavioural sup-
port alone or support plus a placebo; therefore, studies measured
the effect of NRT provided as an adjunct to behavioural support.
Six papers (Berlin 2014; Coleman 2012; Cooper 2014; Kapur
2001; Oncken 2008; Wisborg 2000) described five placebo-
RCTs (Berlin 2014; Coleman 2012; Kapur 2001; Oncken 2008;
Wisborg 2000). Three trials comparedNRTplus behavioural sup-
portwith behavioural support alone (El-Mohandes 2013;Hotham
2006; Pollak 2007), and in these, participants could not be blinded
to treatment. One study used 2 mg nicotine gum (Oncken 2008),
six trials used nicotine patches; the eighth offered a choice of
NRT formulations; approximately two thirds of participants chose
patches and the remainder elected to use gum and lozenges (Pollak
2007).
Four studies used 15 mg/16-hour nicotine patches (Coleman
2012; Hotham 2006; Pollak 2007; Wisborg 2000) and one of
these used a higher nicotine dose (21mg/16-hour) for participants
who reported smokingmore than15daily cigarettes (Pollak 2007).
Two studies attempted to match nicotine doses prescribed with ei-
ther saliva (Berlin 2014), or urinary cotinine levels (El-Mohandes
2013) obtained at earlier appointments. Depending on cotinine
levels, women in one study were treated with combinations of 10
mg and 20 mg 16-hour patches (Berlin 2014), and in the other
with 21 mg, 14 mg or 7 mg 24-hour patches with instructions
to remove these at night (El-Mohandes 2013). One trial advised
women to use trial treatments from randomisation until child-
birth, irrespective of whether or not they relapsed to smoking
(Berlin 2014); others advised women to stop using NRT if they
re-started smoking and had a defined period for use of NRT/trial
patches.
Bupropion study
One study was a placebo-controlled RCT investigating bupropion
which experienced recruitment challenges and randomised only
11 women (Stotts 2015).
Setting
Studies were conducted in the USA (n = 4) (El-Mohandes
2013; Oncken 2008; Pollak 2007; Stotts 2015) Australia (n = 1)
(Hotham 2006), Canada (n = 1) (Kapur 2001), Denmark (n = 1)
(Wisborg 2000), France (n =1) (Berlin 2014) and England (n =
1) (Coleman 2012).
Outcomes
The small bupropion trial (Stotts 2015) (n = 11) ascertained smok-
ing cessation at nine weeks after enrolment (mean gestation at
enrolment = 16 weeks) and in a small NRT trial (n = 40), smok-
ing cessation was ascertained between 20 and 28 weeks’ gestation
(Kapur 2001), but in all others this was ascertained at 32 weeks or
later. In all studies, biological samples were obtained from partici-
pants and, after any necessary clarification with authors, we deter-
mined that all used such samples to validate reported cessation at
the primary endpoint; four studies used exhaled carbon monoxide
(CO) (El-Mohandes 2013; Hotham 2006; Kapur 2001; Oncken
2008), four saliva cotinine (Berlin 2014; Pollak 2007; Stotts 2015;
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Wisborg 2000), and two used both (Coleman 2012; Kapur 2001);
only one reported thiocyanate levels (Kapur 2001) (cut points are
listed in Characteristics of included studies section). For two stud-
ies, cut points were obtained from the trial authors (Pollak 2007;
Wisborg 2000), and we obtained further data on biochemical val-
idation from authors of a trial which used a higher than standard
cut point for saliva cotinine (26 ng/mL) (Wisborg 2000). This
revealed that the cotinine assay used had a lower limit of 20 ng/
mL, which was also above the currently accepted cut point of 10
ng/mL, so some smokers may have been wrongly been categorised
as abstinent in this study.
The periods of abstinence from smoking which participants were
required to demonstrate varied across studies. For smoking out-
comes measured at delivery, three studies reported both seven-day
point prevalence abstinence from smoking and a measure of con-
tinuous abstinence simultaneously (Berlin 2014; Coleman 2012;
Pollak 2007); however definitions varied. One study (Coleman
2012), permitted a small number of temporary lapses to smoking
as recommended by the ’Russell Criteria’ for outcome measure-
ment in smoking cessation studies (West 2005). The remaining
two studies did not permit temporary lapses and defined continu-
ous abstinence as seven-day point prevalence abstinence recorded
on three (Pollak 2007), or up to seven occasions (Berlin 2014).
Four studies reported only seven-day point prevalence abstinence
(Oncken 2008; Pollak 2007; Stotts 2015; Wisborg 2000), and
three reported point prevalence abstinence for an unstated pe-
riod (El-Mohandes 2013;Hotham 2006; Kapur 2001). Four stud-
ies reported seven-day point prevalence abstinence data at time
points after childbirth: Wisborg 2000 provided data at three and
12 months postnatally; Coleman 2012 at six, 12 and 24 months;
Oncken 2008 at six to 12 weeks (biochemically-validated data),
and Pollak 2007 at three months. Additionally, Coleman 2012
reported continuous abstinence between a quit date and each time
point, allowing for temporary lapses too.
Infant and fetal safety outcomeswere reported in six studies (Berlin
2014; Coleman 2012; El-Mohandes 2013; Oncken 2008; Pollak
2007; Wisborg 2000); all six reported mean birthweight, mean
gestation at delivery and the incidences of low birthweight births
(defined as below 2500 g). Five of these studies (Berlin 2014;
Coleman 2012; Oncken 2008; Pollak 2007; Wisborg 2000), re-
ported rates of preterm birth (born before 37 weeks’ gestation),
miscarriage/spontaneous abortion and stillbirth and four trials also
reported infants’ rates of special care admission and neonatal death
(Berlin 2014; Coleman 2012; Oncken 2008; Pollak 2007). Two
trials (Berlin 2014; Coleman 2012) reported data on maternal hy-
pertension in pregnancy and rates of congenital malformation and
caesarean section. Table 1 gives details of twin birth pregnancies
in studies where these occurred; also, for those trials that reported
birth outcomes, this gives details, within singleton pregnancies,
of fetal loss in pregnancy and of subsequent live births. Two tri-
als (Berlin 2014; Pollak 2007) reported with single and multiple
pregnancy data together but, authors supplied data for singleton
pregnancies separately.
With regard to the pre-birth fetal outcomes of miscarriage/sponta-
neous abortion and stillbirth, Oncken 2008 reported that, within
singleton pregnancies, three control group participants had ter-
minations which were performed for social reasons (presumed
healthy fetus), so these fetuses were removed from the denomina-
tor for control group analyses (control group n = 91). Also, Pollak
2007 reported one fetal death prior to randomisation that was
documented by ultrasound scanning (i.e. a ’missed abortion’) in
the NRT group, so this fetus was removed from the denominator
for NRT group (NRT group n = 121). Coleman 2012 reported
one termination and one fetal death prior to randomisation in
women allocated to NRT, so these two cases were removed from
the NRT group denominator (NRT group n = 515). Berlin 2014,
reported one termination in each trial group, with both being con-
ducted for fetal abnormalities which were not assessed as being
compatible with survival at birth. Consequently, as these termina-
tions were undertaken at 25 (placebo group) and 32 weeks, they
have been counted as stillbirths the analysis and remained in the
denominator too.
Only one study reported longer-term smoking and infant out-
comes after birth (Coleman 2012); this trial reported infants’ ’sur-
vival without developmental impairment’„ and respiratory symp-
toms at two years of age and self-reported maternal smoking at
six, 12, and 24 months after childbirth.
Excluded studies
One trial was excluded as it had a quasi-randomised design
(Hegaard 2003); its intervention group was formed by inviting
women with non-even birth dates for antenatal care on days when
the intervention was delivered. Also, NRT was offered to in-
tervention group participants as part of a multi-modal interven-
tion strategy, which was delivered by specially-trained staff who
were only present in antenatal clinics on study days. The control
arm, however, was ’usual care’ delivered by the usual clinic staff;
consequently, it was not judged possible to identify the indepen-
dent effect of NRT on smoking cessation from this study. One
study (Eades 2012) did not specifically deal with a pharmacologi-
cal intervention, but tested another multi-modal one. In this trial,
women were offered NRT following failed quit attempts made
after randomisation at an earlier time point and there was no re-
quirement for participants to agree to use the NRT offered. One
non-randomised study was also excluded (Oncken 2009a).
Risk of bias in included studies
The risk of bias was generally low across trials with virtually all
domains of the ’Risk of bias’ assessment tool being satisfied for the
majority of studies (Figure 1), and an absence of blinding was the
principal difference between trials. Figure 2 shows the degree to
which individual trials met ’Risk of bias’ criteria.
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Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Computer-generated randomnumber sequences were used to gen-
erate randomisation in all studies. One study (Hotham 2006),
used sealed envelopes after random numbers had been generated
but it was not clear if these were opaque and sequentially num-
bered, and another study gave no details of how randomisation
was operationalised (Stotts 2015), so allocation for both studies
was judged to be unclear whilst others were rated as satisfactory
(low risk of bias).
Blinding
This was judged unsatisfactory in studies that had no placebo
control - it was the principal difference between studies judged
likely to cause bias. Six trials were placebo-RCTs (Berlin 2014;
Coleman 2012; Kapur 2001; Oncken 2008; Stotts 2015;Wisborg
2000), and three compared behavioural support alone with NRT
and behavioural support (El-Mohandes 2013; Hotham 2006;
Pollak 2007).
Detection bias (biochemical validation of smoking
outcomes)
In smoking cessation studies, bias can occur at outcome ascertain-
ment if trial participants report that they have stopped smoking
when actually they have not. Generally, it is perceived that the
broadly negative social view of smoking can result in self-perceived
pressure on participants in smoking cessation studies to be seen as
having successfully stopped smoking and this may result in false
reporting of abstinence from smoking at follow-up. Trialists at-
tempt to minimise this bias (detection bias) through use of bio-
chemical validation of self-reported smoking status data which is
collected for trial outcomes. As all included trials validated self-re-
ported smoking outcomes, this is not a major issue for this review.
However, one included study (Wisborg 2000) used a cut point for
saliva cotinine (26 ng/mL), which was substantially higher than
the currently accepted level (10 ng/mL) and, additionally, used an
assay with a lower limit of measurement of 20 ng/mL (i.e. samples
in the 0 to 20 ng/mL range were reported as 20 ng/mL (Wisborg
2000). This means that, in this study, some of those few partici-
pants who falsely reported themselves as not smoking might have
had their false reports of abstinence validated as true (i.e. some par-
ticipants who were actually smoking might not have had this de-
tected by the validation process). Of course, no validation process
is perfect and, using any cut point, some false reports of cessation
would be accepted as true, but with a known high cut point as in
(Wisborg 2000), one would expect this to occur more frequently.
However, the use of biochemical validation in this study would be
still be expected to detect heavier smokers who made false reports
of abstinence, so validated data from this study were still used in
preference to self-report data. The one bupropion study (Stotts
2015) also used a relatively high cut point (20 ng/mL), so similar
issues are also relevant to this trial.
Incomplete outcome data
This was judged to be satisfactory across all studies; for smoking
data an intention-to-treat analysis was followed in all studies, so
that those participants who could not be contacted at follow-up
were assumed to have returned to smoking. This approach assumes
that where data on smoking status are missing, participants are
smoking; it should be noted that this assumption is conservative
and is the standard approach taken when assessing the efficacy
of smoking cessation interventions. Follow-up for birth outcomes
was generally high with one exception. The treatment group allo-
cation for seven women who experienced miscarriage after being
randomised within one study (Wisborg 2000), could not be as-
certained, so this trial was rated as being unclear with respect to
this criterion.
Selective reporting
Four studies were judged unsatisfactory with respect to selective
reporting bias. Hotham 2006 and Stotts 2015 both collected data
on a number of outcomes that were not reported in the trial
manuscript; for Hotham 2006, we unsuccessfully requested birth-
weight data for this review’s meta analysis. El-Mohandes 2013 et
al informed the review team that within their trial, some data on
secondary smoking cessation outcomes were collected, but this
had not been reported within the trial manuscript; in both stud-
ies, primary outcomes were reported, however. No birth outcomes
were reported in Kapur 2001.
Other potential sources of bias
In one study (El-Mohandes 2013), an unanticipated potential
source of bias was identified; two participants were screened
and randomised on two separate occasions, each pregnancy was
counted as a discrete study participation and both women were
included twice in the trial analysis. This was considered as having
the potential to introduce bias into what was a relatively small
study and this was, therefore allocated a ’high’ ’Risk of bias’ as-
sessment. Both Hotham 2006 and Pollak 2007 were also judged
to be at high risk of other bias, due to concerns regarding lack of
blinding using a placebo.
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Effects of interventions
Primary outcomes (efficacy)
In a pooled analysis of eight included studies and 2199 partic-
ipants, there was an indication that NRT as an adjunct to be-
havioural support is effective for smoking cessation in pregnancy
(risk ratio (RR) (1.43, 95% confidence interval (CI) 1.03 to 1.93,
Tau² = 0.03, I² = 18%, Analysis 1.1).
In the subgroup analysis that compared active NRT with placebo,
heterogeneity between studies was substantially reduced and al-
though the risk ratio for smoking cessation with NRT was lower
but in the same direction, it was not significant (RR 1.28, 95%
CI 0.99 to 1.66, Tau² = 0.00, I² = 0%, five studies, 1926 women,
Analysis 1.1), whereas, the estimate derived fromnon-placebo con-
trolled trials indicated efficacy (RR 8.51, 95% CI 2.05 to 35.28,
Tau² = 0.00, I² = 0%, three studies, 273 women) (P value for
random-effects subgroup interaction test = 0.01; see Analysis 1.1).
The planned sensitivity analysis relating to adherence with treat-
ment could not be conducted as trials reported adherence so dif-
ferently that it was not possible to categorise one or more trials
as having substantially worse or better treatment adherence than
others.
The impact of NRT as an adjunct to behavioural support on cessa-
tion at time points after childbirth was investigated by pooling data
from studies that provided postnatal follow-up data on smoking
behaviour. In a pooled analysis of studies which reported non-val-
idated seven-day point prevalence of abstinence from smoking at
or before six months after childbirth (predominantly at or around
three months), there was no evidence that NRT compared to
placebo or non-placebo controlled trials was effective for smoking
cessation; (RR for cessation with NRT versus placebo 1.15, 95%
CI 0.75 to 1.77, Tau² = 0.00, I² = 0%, two studies, 444 women
Analysis 1.2). Although this analysis included a large trial with
follow-up at six months (as opposed to three months), removing
this study from the analysis did not substantially alter findings, in-
dicating no effect for NRT when using data from studies in which
all collected data close to the three-month time point. Similarly,
the pooled estimate for non-validated seven-day point prevalence
of smoking abstinence RR of NRT compared to placebo at one
year after childbirth did not indicate that NRT had an effect at
this time point; RR 1.04, 95% CI 0.57 to 1.88, Tau² = 0.00, I²
= 0%, one study, 246 women Analysis 1.3. The one study which
monitored continuous cessation from a quit date set in pregnancy
to postnatal time points alongside seven-day point prevalence ab-
stinence data collected at the same time points (Coleman 2012)
reported higher point prevalence than continuous cessation rates
at each time point and rates of continuous cessation until two
years after childbirth were low (2.9% in NRT group versus 1.7%
in placebo, adjusted P value = 0.12).
In the one trial of bupropion (Stotts 2015), two (out of five)
placebo group participants had validated smoking cessation, but
no bupropion group participants reported abstinence.
Secondary outcomes (safety)
Two study papers reported birth outcomes from single and multi-
ple birth infants together (Berlin 2014; Pollak 2007) and authors
kindly provided data on birth outcomes within singleton preg-
nancies only. Table 1 gives details of twin births and fetal loss in
pregnancy.
There was no significant difference in risk of miscarriage/sponta-
neous abortion between trials NRT and control groups (RR 1.47,
95% CI 0.45 to 4.77, Tau² = 0.00, I² = 0%, four studies, 1782
women, Analysis 2.1). However, despite contacting study authors,
we could not determine the treatment allocation for seven miscar-
riages from one study, which is not included in this comparison
(Wisborg 2000). If we assume that all miscarriages from this study
occurred in either the NRT or control groups (i.e. the extremes of
how these could actually be distributed), this results in the follow-
ing effect estimates: (all assumed in NRT group, RR 1.82, 95%
CI 0.59 to 5.64; all assumed in control group, RR 0.74, 95% CI
0.19 to 2.81). NB: these are hypothetical scenarios including par-
tially-hypothesised data and so, are not included with presented
findings. There was no significant difference between the numbers
of stillbirths in the NRT and control arms of trials (RR 1.24, 95%
CI 0.54 to 2.84, Tau² = 0.00; I² = 0%, four studies, 1777 women,
Analysis 2.2).
The pooled estimate for control groupbirthweightwas higher than
for the NRT group, but this difference was not significant (mean
difference (MD) 100.54 g, 95% CI -20.84 to 221.91, Tau² =
15624.49, I² = 75%, six studies, 2068 women), and heterogeneity
was high and on the borderline for presenting pooled estimates
(Analysis 2.3); consequently, the result for this comparison must
be interpreted with caution. Reasons for this heterogeneity are
unclear; it is not easily explained by study design as one large
placebo-RCT (Coleman 2012) and a smaller non-placebo one
(Pollak 2007), in contrast to other studies, both reported non-
significantly lower birthweight in NRT group infants. There was
a lower incidence of low birthweight births in NRT group women
but again, this was not significant and was found in the context of
much heterogeneity so caution is again warranted (RR 0.74, 95%
CI 0.41 to 1.34, Tau² = 0.33, I² = 71% six trials, 2037 women,
Analysis 2.4). Again, the pattern of heterogeneity was difficult to
understand; the same two studies (Coleman 2012; Pollak 2007)
reported non-significantly higher rates of low birthweight infants
in the NRT arm.
Preterm births (RR 0.87, 95% CI 0.67 to 1.14, Tau² = 0.00, I²
= 0%, six studies, 2048 women, Analysis 2.5), neonatal intensive
care unit admissions (RR 0.90, 95% CI,0.64 to 1.27, Tau² = 0.00,
I² = 0%, four studies, 1756 women, Analysis 2.6), and neonatal
deaths (RR 0.66, 95% CI 0.17, 2.62, Tau² = 0.00, I² = 0%, four
studies, 1746 women, Analysis 2.7), were all less frequent in NRT
groups, but differences between NRT and control groups were
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not significant. It was possible to meta-analyse rates of congenital
anomalies and of caesarean birth in NRT and control groups (two
studies, Berlin 2014; Coleman 2012, 1401 women) (Analysis 2.8
and Analysis 2.9 respectively). There was no significant difference
in rates of congenital anomaly (RR 0.73, 95% CI 0.36 to 1.48,
Tau² = 0, I² = 0%), or in caesarean section rates (RR 1.18, 95%CI
0.83, 1.69, Tau² = 0.03, I² = 46%) between trial groups. The two
studies that provided data on hypertension gave these in differ-
ent formats; Coleman 2012 reported that 24 (4.6%) in the NRT
group compared to 25 (4.7%) in placebo were noted to have hy-
pertension in pregnancy (i.e. blood pressure of greater than 140/
90 mmHg) on at least two occasions (no statistical comparison
presented). Berlin 2014 reported significantly higher median di-
astolic blood pressure in the NRT group [median BP = 70, in-
terquartile range (IQR) = 60 to 80 mmHg] compared to placebo
[median BP = 62, IQR = 60 to 80 mmHg], (P = 0.02). Berlin
2014 also reported an interaction between treatment group and
time (i.e. during pregnancy) for increases in diastolic blood pres-
sure (BP), though absolute increases in BP were small.
Coleman 2012 and Berlin 2014 also reported the distribution of
other birth outcomes between NRT and placebo groups such as
Apgar score at five minutes after birth, cord arterial blood pH,
intraventricular haemorrhage, neonatal convulsions, necrotising
enterocolitis, mechanical ventilation of infant, assisted vaginal de-
livery and maternal death; no statistically significant differences
were noted.
In the bupropion trial (Stotts 2015), there was no significant dif-
ference in mean birthweight or mean length of infants in trial
groups.
Coleman 2012 was the only study identifiedwhich reported infant
outcomes after the neonatal period. Using a composite, self-report
outcome based on the ’Ages and Stages Questionnaire 3rd Edition
(ASQ-3)’ instrument (Squires 2009), significantly better infant
developmental outcomes were observed in infants born to women
who had been randomised to NRT; compared to placebo group
infants for those born in the NRT group, the odds ratio (OR)
for infant survival to two years of age ’without impairment’ (i.e.
normal development) was 1.40, 95% CI 1.05 to 1.86. However,
there was no difference in parental reports of infants’ respiratory
symptoms; OR for reporting of any respiratory problem in NRT
group was 1.32, 95% CI 0.97 to 1.74.
Adherence/compliance and side effects
Where adherence was reported, this was generally low as the ma-
jority of participants in all studies did not use complete courses
of NRT offered; Table 2 summarises adherence data reported in
trials. Berlin 2014 differs from other studies in that transdermal
patches were offered to women between their quit dates and de-
livery. Much higher self-reported adherence rates are noted from
this study; however it is difficult to reconcile these with reported
rates of intervention discontinuation and direct comparison with
other studies is not possible.
Only a narrative reporting of non-serious side-effect data is pos-
sible. Five trials reported non-serious side effects (Berlin 2014,
Coleman 2012; Hotham 2006; Oncken 2008; Wisborg 2000):
one reported their frequency within women using NRT, noting
that five (25%) participants in the NRT group experienced minor
symptoms and two women stopped using patches after unpleas-
ant effects (Hotham 2006). However, this trial did not monitor
non-serious symptoms in the control group, so this figure is dif-
ficult to interpret. Oncken 2008 reported that at least 10% of
participants experienced headache, dizziness, fatigue, heartburn,
nausea or vomiting, with 14 (15%) in the NRT and 12 (12%) in
the control groups discontinuing treatment due to adverse effects.
Wisborg 2000 noted that 11 participants stated that adverse ef-
fects (e.g. skin irritations and headache) made them discontinue
patches, but did not report treatment allocations; also five partici-
pants in this trial reported palpitations and two nausea. Coleman
2012 noted 535 non-serious adverse events reported by 521 NRT
group participants and 450 reported by the 529 placebo group
ones. Berlin 2014 reported a range of non-serious adverse events
noting that more non-gynaecological ones occurred in the NRT
group, but this was principally due to skin reactions. In this study,
11% of participants in the NRT suffered a skin reaction at the
patch site compared with 4% in the placebo one.
Sensitivity analyses
The two potential sensitivity analyses were not undertaken. All
studies provided biochemically-validated outcome data at deliv-
ery so no validated/non-validated comparison was possible. Ad-
herence data (above) were so variably recorded that no synthesis
or comparison was possible.
D I S C U S S I O N
Summary of main results
There is evidence of borderline significance suggesting that nico-
tine replacement therapy (NRT) used with behavioural support
by pregnant women for smoking cessation may increase smoking
abstinence in late pregnancy by approximately 40%. There was no
consistent evidence of NRT having either a positive or negative
impact on birth outcomes but findings from the only trial which
followed infants after the neonatal period found that those born
to NRT group women were less likely to experience developmen-
tal impairment which suggests that NRT used in pregnancy may
improve infant developmental outcomes.
There was only one small bupropion trial and none of varenicline
or electronic nicotine delivery systems (ENDS).
Caution is required when interpreting the pooled estimate for the
effect of NRT, used in pregnancy, for smoking cessation in later
pregnancy as subgroup analyses revealed very different treatment
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effects fromplacebo andnon-placebo controlled studies suggesting
clinical heterogeneity; it is possible that these findings occurred
because of unexplained biases, presumably within the less robust,
non-placebo controlled trials. The actual efficacy of NRT used for
smoking cessation in pregnancy may, therefore, be closer to the
risk ratio estimate derived from placebo-controlled trials, which
reached only borderline significance (Analysis 1.1).
Overall completeness and applicability of
evidence
As the only difference between the arms of included trials was
the provision of pharmacotherapy versus placebo or no placebo to
all participants, we have isolated the independent effects of NRT
which are of most importance to clinicians and policy-makers.
It has been mandatory, since July 2005, for clinical trials to be
recorded on a trials register so, we are confident that our method
of searching for those that reported after the previous Cochrane
searches were conducted will have identified all relevant research
reports. Findings reported in this review are based on currently-
accepted, evidence-based cut points for determining abstinence
from smoking (SRNT2002), rather than ones which might have
been acceptable in the past, enhancing the validity of findings.
Quality of the evidence
Included trials were generally of a high standard; the principal
difference in studies’ propensity to bias was judged to come from
the use/non use of placebo controls. Trials which used a placebo-
controlled design were considered to be at a lower risk of bias than
those which did not; the reduction in heterogeneity observed after
dividing trials according to this criterion seems to vindicate this
judgement.
Potential biases in the review process
The search for studies in this area was performed using the
Cochrane Pregnancy and Childbirth Group’s Trials Register
(which is updated weekly to monthly with information from
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, Embase, handsearches from 30 journals and confer-
ence proceedings of major conferences and alerts for a further 44
journals). It is unlikely that studies that have been conducted have
been missed, however unpublished studies, or ongoing studies not
registered in clinical trial registries could be missing. Should such
studies be identified, we will include them in future updates of the
review.
We aimed to reduce bias wherever possible by having at least two
review authors independently working on study selection, data
extraction and ’Risk of bias’ assessment.
Agreements and disagreements with other
studies or reviews
This review explicitly assesses the efficacy and safety of pharmaco-
logical therapies used for smoking cessation in pregnancy. Some
trials of smoking cessation in pregnancy test NRT as part of multi-
modal intervention strategies and these are included in an asso-
ciated review (Chamberlain 2013). However, this review is con-
cerned with the efficacy and safety of pharmacological therapies
when used for smoking cessation in pregnancy, and examines the
independent safety and efficacy of pharmacological interventions.
Since the previous version of this review was published (Coleman
2012) another systematic review which investigates the efficacy
of smoking cessation medications in pregnancy (Myung 2012)
and a critique (Coleman 2013) have been published. Searches
for the (Myung 2012) review were completed before three stud-
ies included in the current review were published (Berlin 2014;
Coleman 2012: El-Mohandes 2013); additionally this included
the large non-randomised trial described above which was ex-
cluded from the current review (Hegaard 2003) and a non-RCT
investigating bupropion (Chan 2005). Myung 2012 et al con-
cluded that ’pharmacotherapy had a significant effect on smoking
cessation’ (risk ratio 1.80; 95% confidence interval 1.32 to 2.44).
However, as this analysis pooled bupropion and NRT studies to-
gether, clinical implications are uncertain. Additionally, the effi-
cacy estimate is likely to be inflated by inclusion of a large quasi-
RCT which tested the offer of NRT as part of a multi-modal
cessation intervention (Hegaard 2003) and the deployment of a
’fixed-effect’ approach to meta-analysis. We believe that accruing
evidence suggests that placebo and non-placebo RCTs produce
different findings and, so a ’random-effects’ approach is better jus-
tified.
A systematic review of trials conducted in non-pregnant women
has shown thatNRT is effective outside of pregnancy (Stead 2012);
however, the reasons why this does not appear to be the case in
pregnancy are not known. Participants in trials included within
the current reviewmade relatively little use of offeredNRT and, as
NRT can only be effective if it is actually used, low adherence with
therapy may explain review findings. If low adherence explains
the difference in findings between this and the ’non-pregnancy’
NRT review (Stead 2012), then understanding the phenomenon
of low adherence could be important. Another possible explana-
tion for lack of efficacy noted in pregnancy could be that increased
metabolism of nicotine in pregnancy (Dempsey 2001) results in
NRT generating lower blood nicotine levels in pregnancy and this
reduced nicotine substitution could, in turn, increase women’s ex-
perience of withdrawal symptoms causing them to stopNRTearly.
Logically, if in trials to date, increased metabolism underpinned
women’s low adherence with NRT, higher doses of NRT could be
needed for this to be effective in pregnancy.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There isweak evidence to suggest that usingNRTwith behavioural
support for smoking cessation in pregnancy is effective; there is
no evidence that NRT has either a positive or negative impact
on pregnancy and infant outcomes. Efficacy findings should be
treated cautiously as their derivation includes data from non-
placebo RCTs which appear to have higher risks of bias. It is pos-
sible that the actual efficacy of NRT in pregnancy is better rep-
resented by the borderline significant findings from meta-analysis
of placebo-RCTs. NRT is already used quite widely in some juris-
dictions and accruing evidence is that this clinical practice does no
harm, with evidence from one trial suggesting that NRT used in
pregnancy for smoking cessation results in improved child devel-
opment (Coleman 2012). There was only one trial of bupropion
and none investigating varenicline or ENDS; and so we cannot
comment on their use in pregnancy.
Implications for research
As most included trials involved standard doses of NRT (princi-
pally 15 mg, delivered via a 16-hour patch), further RCTs should
focus on the dose of NRT employed. There are strong reasons to
suspect that NRT used at higher doses than in most trials within
this review, could be effective in pregnancy and large, well-con-
ducted placebo-RCTs investigating the efficacy and safety of higher
doses of NRT in pregnancy should be conducted. RCTs of higher-
dose NRT should attempt to increase adherence with treatment
and they should also monitor infant outcomes to seek replica-
tion of SNAP (Smoking, Nicotine, and Pregnancy) trial findings
(Coleman 2012); there is no evidence that NRT is harmful in
pregnancy, indeed what evidence there is indicates that it may be
beneficial for infants. Qualitative research designed to gain under-
standing of why pregnant women have low adherence with NRT
is needed. Future studies could increase adherence by permitting
women who smoke temporarily to continue using transdermal
patches or other trial treatments and also by providing NRT or
placebo throughout pregnancy; both approaches were employed
by Berlin 2014. Studies investigating bupropion and varenicline,
if judged ethical, are also needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Berlin 2014
Methods Double-blind, placebo-controlled, parallel-group RCT.
Participants Pregnant women aged ≥ 18 years, between 9 and 20 weeks’ gestation who smoked at
least 5 daily cigarettes and scored at least 5 on a scale measuring motivation for quitting
smoking (range 0-10)
Interventions Intervention and control differed only in the provision of active or visually-identical
placebo transdermal patches. The intervention patch delivered nicotine as nicotine re-
placement therapy over a 16-hour period. Both 10 mg and 15 mg patches were used and
women’s doses does ranged from 10mg to 30mg per day. A saliva sample was collected at
women’s first trial visit/contact with the research team. Between this and a second visit/
contact, which occurred 2 weeks later, women were instructed to either stop smoking
or to reduce this to less than 5 daily cigarettes. Women who managed to reduce or stop
smoking in this way were, at their second visit, randomised to either placebo or active
patch in a 1:1 ratio. The nicotine dose used for women’s first prescription of NRT (made
at this 2nd trial visit) was based on their saliva cotinine level obtained from the sample
given at visit 1 with the aim being to attempt 100% substitution of nicotine obtained
from smoking for that obtained via patches
Women were instructed to use NRT from their quit date until delivery. Smoking and
using patches was not encouraged (this is described as a ’safety concern’). However, if
women did have a temporary lapse to smoking, they were allowed to remain on NRT
afterwards. Both groups received counselling on how to use patches
Outcomes Therewere 2primary outcomes, 1maternal and1 relating to infants; thesewere complete,
continuous abstinence from smoking since the quit date and infant birthweight. A
positive abstinence outcome was recorded where women self-reported 7 days abstinence
from smoking at each study visit and this was confirmed by an exhaled CO reading of 8
ppm or less. There were up to 7 study visits with the final 1 intended for 1 month prior
to delivery; no lapses from smoking were permitted
Notes The cessation outcome used was more stringent than in many studies; often some al-
lowance for temporary lapses to smoking is permitted and many studies assess smoking
status as a smaller number of time points in pregnancy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated randomisation list
(allocation ratio 1:1) in blocks of 4 was
prepared and kept double-blinded. 60 ran-
domisation numbers were established by
centre. In case of more than 60 randomisa-
tions by centre, the next randomisation list
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of 60 was added. The randomisation list by
centre was incorporated into the electronic
case report form, and the randomisation
number was attributed automatically at the
completion of the randomisation visit
Allocation concealment (selection bias) Low risk A statistician at the clinical research cen-
tre of the Assistance publique-Hôpitaux de
Paris, who was fully independent of the
trial, prepared the random, computer-gen-
erated allocation sequence. The randomi-
sation code was kept in a sealed envelope
in a safe. A copy of the randomisation code
was kept separately in case of a serious ad-
verse event necessitating exposure of a par-
ticipant’s group assignment. Investigators,
members of the co-ordination centre, hos-
pital pharmacists, and the study statisti-
cian were kept blinded until the code was
opened before witnesses on 19 February
2013
Blinding (performance bias and detection
bias)
Women and clinical staff
Low risk All study staff (investigators, pharmacists,
members of the co-ordination centre and of
the drug safety monitoring board, labora-
tory staff, statistician) were double-blinded
to treatment allocation. Placebo patches
were identical (visually) to active ones. De-
termination of saliva cotinine levels were
carried out blinded and investigators were
not aware of the results
Incomplete outcome data (attrition bias)
All outcomes
Low risk There are similar rates of attendance rates
for all trial visits but there are no data pre-
sented on attendance at individual trial vis-
its; however, for smoking outcomes all who
could not be contacted are assumed to be
still smoking so the potentially low follow-
up rates do not affect this. Follow-up rates
for birth outcomes are high (e.g. only 3 par-
ticipants had no delivery data)
Selective reporting (reporting bias) Low risk All pre-specified outcomes appear to have
been reported
Detection bias (biochemical validation of
smoking outcomes)
Low risk Exhaled CO used with cut point of 8 ppm
or less used to validate 7 days abstinence
from smoking
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Overall assessment of bias risk Low risk See all of above; no substantial sources of
bias identified.
Coleman 2012
Methods Double-blind placebo-controlled RCT - stratified by trial centre only
Participants Pregnant women (n = 1050) who agreed to set a quit date, were 16 to 50 years of age,
were at 12 to 24 weeks of gestation, smoked 10 or more cigarettes daily before pregnancy,
currently smoked 5 or more cigarettes daily, and had an exhaled CO concentration of at
least 8 ppm
Interventions Intervention and control conditions differed only in the provision of transdermal patches;
the intervention group received active and the control group, placebo patches. Research
midwives were trained to provide behavioural support according to national standards,
with the use of a manual that included guidance from a British expert trainer of smok-
ing-cessation professionals and behavioural approaches from the Smoking Cessation or
Reduction in Pregnancy Treatment trials that were believed to be relevant to British
smokers. At enrolment, research midwives provided behavioural support lasting up to
1 hr, and participants agreed to a quit date within the following 2 weeks; follow-up was
timed from the quit date. Subsequently, participants were randomly assigned to receive
a 4-week supply of transdermal patches for nicotine-replacement therapy (at a dose of
15 mg per 16 hrs) or visually identical placebos, which were started on the quit date (all
study treatment was purchased at market rates from United Pharmaceuticals). 1 month
after the quit date, women who were not smoking, as validated by an exhaled CO con-
centration of less than 8 ppm, were issued another 4-week supply of patches.
In addition to behavioural support at enrolment, research midwives provided 3 sessions
of behavioural support by telephone to participants: 1 session on the quit date, 1 session
3 days afterward, and 1 at 4 weeks. The women who collected a second month’s supply
of nicotine-replacement or placebo patches also received face-to-face support from the
research midwife at the time of collection. Women were offered additional support from
local National Health Service smoking cessation services and were encouraged to ask
for support from the research midwives or smoking cessation service staff; support was
provided according to the manual
Outcomes Prolonged smoking cessation between a quit date soon after enrolment and delivery,
validated by both exhaled CO monitoring and saliva cotinine estimation. Cut points:
exhaled CO, smoking was defined as > 7 ppm, saliva cotinine, smoking defined as > 9 ng/
dL. Birth outcomes including Apgar score at 5 mins after birth, cord arterial blood pH,
intraventricular haemorrhage, neonatal convulsions, congenital abnormalities, necrotis-
ing enterocolitis, mechanical ventilation of infant, assisted vaginal delivery, maternal
death and caesarean section
For infants: survival to 2 years of age without developmental impairment, reported
respiratory symptoms.Maternal: self-reported abstinence from smoking for at least 7 days
reported at 6, 12 and 24 months after childbirth, prolonged abstinence from smoking
since a quit date set in pregnancy and until 24-month follow-up (defined as having
validate abstinence at delivery followed by reported abstinence at all outcome points
listed above
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence, in random
permuted blocks of randomly varying size
and with stratification by recruiting site
Allocation concealment (selection bias) Low risk Allocation and dispensing of treatment/
placebo packages by external clinical tri-
als unit, with all study staff and partici-
pants unaware of study allocation. “Iden-
tically packaged study patches were dis-
pensed, and all participants and study per-
sonnel were unaware of the study assign-
ments”
Blinding (performance bias and detection
bias)
Women and clinical staff
Low risk From the text of the paper, it was clear that
participants and clinicians were adequately
blinded
Although the report does not state the out-
come assessor was blinded adequately, this
was confirmed in communication with the
Chief Investigator who stated that the clin-
icians acted as outcome assessors and were
completely blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant excluded post randomisation
due to accidentally being enrolled twice
(control group) and all except this partic-
ipant were included in intention-to-treat
analysis
Intervention: 36 were excluded: (24 were
lost to follow-up, 3 withdrew consent, 9
had fetal or infant death)
Control: 33 were excluded: (22 were lost to
follow-up, 7 withdrew consent, 4 had fetal
or infant death
Also, groups appeared balanced at follow-
up with 60% follow-up rates for smoking
outcomes and much higher for infant ones
Selective reporting (reporting bias) Low risk Very detailed report of all outcomes and ad-
verse outcomes.
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Detection bias (biochemical validation of
smoking outcomes)
Low risk Biochemical validation of smoking cessa-
tion conducted at follow-up points prior to
and around childbirth but not afterwards
Overall assessment of bias risk Low risk Only 1 item was independently coded as
unclear (and remains as such). However,
clarification from theChief Investigator in-
dicates that this item should be regarded as
’low risk’ because outcome assessors were
completely blinded
El-Mohandes 2013
Methods Non-placebo parallel-design RCT.
Participants English speaking pregnant women who smoked and were residents ofWashington DC in
the United States, of ethnic minority backgrounds, aged at least 18 years and less than 30
weeks’ gestation. Women needed to express a, desire to quit and have an expired air CO
reading of 8 ppm or less and a salivary cotinine of 20 ng/mL or less (NB: clincialtrials.
gov website says 30 ng/mL: or less) or a urinary cotinine of 100 ng/mL or less
Interventions 1:1 ratio randomisation, stratified by site and initial salivary cotinine levels to either 1)
cognitive behavioural therapy (CBT) and NRT transdermal patches or 2) CBT alone
NRT: a 10-week course of 24-hour patches was offered, with initial dosing varying with
baseline salivary cotinine measurements.Womenwith levels of≥ 100 ng/mLwere issued
with 21 mg patches for 2 weeks, 14 mg patches for 4 weeks, and finally 7 mg patches for
4 weeks. Women with levels of ≥ 20 ng/mL and ≤ 100 ng/mL were issued with 14 mg
patches for 6 weeks and 7 mg patches for 4 weeks. The first batch of patches was issued
at the second study visit at which salivary cotinine levels were available
Participants were given clear verbal and written instructions on patch use. They were
advised never to smoke while using the patch, to remove the patch before going to sleep
and not to use other NRT concurrently
CBT: this was the same for both groups.
Outcomes Smoking cessation outcome: during the study participants made 6 visits to the study
team in the antenatal period. At visit 2 (V2), trial interventions were initiated and at
each of visits V3-V6 (the last before childbirth), women were asked if they had smoked
since their previous clinic visit (e.g. at V3, they were asked if they had smoked since V2)
. Participants who reported smoking cessation had this validated using exhaled CO with
abstinence viewed as confirmed by a reading of < 8 ppm. The trial manuscript reports
point prevalence of abstinence from smoking at each time point and data from V6 are
used in analyses. All data were validated (self-report not available), but the period of
abstinence which was validated is unclear and varied with the interval between clinic
visits
Secondary outcomes reported in the trial manuscript are: premature birth (i.e. at < 37
weeks’ gestation); gestational age at birth; mean birthweight and low birthweight < 2500
g. Authors have clarified that the following outcomes were collected too: ability to not
smoke for 24 hrs or more; longest number of days the woman was able to go without
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even a puff of smoking; frequency of smoking at least puff during the last 7 days; number
of cigarettes smoked each day; the number of cigarettes smoked during the past 24 hrs
and frequency of use of other forms of tobacco
Notes TItle of paper states it was conducted in ’African-American smokers’, but in manuscript
participants are described as ’ethnic minority women’ and inclusion criteria on clinical-
trials.gov includes Hispanic women
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in a 1:1 ratio was stratified by site
and initial salivary cotinine levels. A web-based
database management system was programmed to
randomise after entering the necessary data to ver-
ify eligibility
Allocation concealment (selection bias) Low risk Randomisation is remote from research staff, so
this seems appropriate (see text from manuscript
above)
Blinding (performance bias and detection
bias)
Women and clinical staff
High risk No placebo so participants cannot be blind to
treatment allocation; however those delivering be-
havioural intervention were blind to participants’
treatments and the intensity of interventions/con-
tact with participants was standardised in both
groups. Those conducting telephone interviews
were blind to allocation and smoking behaviour
data ’was collected through a self-administered
form, completed and sealed by the participant at
the end of visits 2-6 and only available to re-
searchers at the end of the study’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat appears to have been conducted
adequately for smoking outcomes and there was
relatively little data attrition for infant outcomes,
so risk of bias is considered low
Selective reporting (reporting bias) Unclear risk Adherence data were collected but this is not
reported. Some secondary outcomes (regarding
smoking) were not reported
Detection bias (biochemical validation of
smoking outcomes)
Low risk Exhaled CO validation using a cut point of < 8
ppm was used.
Overall assessment of bias risk High risk In addition to issues highlighted above, 2 women
were screened and randomised twice - each preg-
nancy counted as separate study participation and
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both were included in the analysis. Additionally, 1
NRT and CBT group woman received no NRT;
given the small size of this trial, both issues could
introduce bias
Hotham 2006
Methods Non-placebo parallel-design RCT.
Participants 40 healthy Australian women between 12 and 28 weeks pregnant and smoking >= 15
cigarettes daily with an exhaled breath CO reading of > 8 ppm
Interventions Control group: 5-minute counselling at baseline and further brief counselling (< 2-minte
duration) at follow-up visits.
Intervention: counselling as above plus an element concerning correct use of NRT plus
15 mg/16-hour patches for a maximum of 12 weeks.
Outcomes Smoking cessation (point prevalence) at final antenatal visit
Women seen ‘at least monthly during gestation’; also seen within 48 hrs of delivery when
exhaled CO and saliva sample (for cotinine) taken and by telephone at 6 weeks and 3
months
Notes Exhaled CO readings used to validate point prevalence cessation at final antenatal visit.
Cut point = 8 ppm CO. Author clarification used to obtain this information as not
clear in research report. No data on smoking outcomes after childbirth are reported in
the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence.
Allocation concealment (selection bias) Unclear risk Described as “sealed envelope system”. Unclear
whether envelopes opaque
Blinding (performance bias and detection
bias)
Women and clinical staff
High risk No placebo was used. Unclear if assessors blinded
to allocation of treatments
Incomplete outcome data (attrition bias)
All outcomes
Low risk 14/40withdrew from the study (35%attrition). All
withdrawals included in this analysis as continuing
smokers
Selective reporting (reporting bias) Unclear risk Author confirmed that the following outcomes col-
lected: mode of delivery, labour interventions (if
any), birthweight, Apgar scores at 1 and 5mins, re-
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sults of cord-blood analysis for pH and base excess
and also for carboxyhaemoglobin and cotinine
Author asked toprovide birthweight data to inform
safety analyses
Detection bias (biochemical validation of
smoking outcomes)
Low risk Exhaled CO and salivary samples.
Overall assessment of bias risk High risk A trial at greater risk of bias.
Kapur 2001
Methods Parallel-design RCT with active and placebo patches and clinicians/researchers and par-
ticipants unaware of allocation
Participants 30 healthy Canadian women between 12 and 24 weeks pregnant and smoking >= 15
cigarettes daily who want to quit smoking and could not do so in 1st trimester.
Interventions 12 week course of NRT or identical placebo patches: 15 mg/18hour patch for 8 weeks,
then 10 mg/18-hour for 2 weeks and finally 5 mg/18-hour for 2 weeks. Behavioural
counselling at baseline and all follow-up points. Counselling at baseline including a
video explaining how to use patch; also counselling at all follow-ups. Weekly telephone
contact with women
Intervention = active patch, control = placebo.
Outcomes Smoking cessation (unclear if point prevalence or continuous cessation measured) 8
weeks into programme (20-32 weeks into pregnancy)
Follow-up also at weeks 1 and 4 into programmewith saliva and serum cotininemeasured
at all time points
Notes Primary outcome validated at 8 weeks into programme. Cotinine cut point not stated
but paper states that ‘in no case was smoking cessation associate with thiocyanate levels
of > 1 ug/ml’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number sequence - confirmed by
authors.
Allocation concealment (selection bias) Low risk Placebo or active patches packed remotely
as per the randomisation sequence - confir-
mation via contact with author
Blinding (performance bias and detection
bias)
Women and clinical staff
Low risk Described as participants and researchers
or clinicians unaware of treatment allo-
cation with identical active and placebo
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NRTpatches, althoughmost women in the
placebo group did not complete the pro-
gramme
Incomplete outcome data (attrition bias)
All outcomes
Low risk Biochemical validation missing for approx-
imately a third of the sample. All drop-
outs and missing data treated as continuing
smokers in this analysis
Selective reporting (reporting bias) Unclear risk No birth outcomes reported.
Detection bias (biochemical validation of
smoking outcomes)
Low risk Biochemical validation by serum thio-
cyanate and salivary cotinine
Overall assessment of bias risk Low risk At lower risk of bias.
Oncken 2008
Methods Parallel-design RCT with active and placebo NRT gum and clinicians/researchers and
participants unaware of allocation
Participants 194 healthy, US English/Spanish-speaking women <= 26 weeks pregnant, smoking >=
1 cigarette daily and aged >=16 years
Interventions 12 weeks treatment with either 2 mg NRT gum or identical placebo. 6 weeks full
treatment was followed by 6 weeks tapering of treatment. Instructed not to chew >
20 pieces daily and to use 1 piece of gum for each substituted cigarette. Additionally,
all participants received individual counselling at baseline and all 8 follow-ups - 2, 35-
minute counselling sessions at baseline andwithin 1week of quit date and shorter sessions
at other follow-ups
Intervention = active gum, control = placebo.
Outcomes Self-reported 7-day point prevalence abstinence at 6 weeks after treatment commenced,
at 32-35 weeks of pregnancy and at 6-12 weeks after delivery. Exhaled CO of less than
8 ppm used for validation all time points
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised randomisation program to
balance participant assignment into treat-
ment groups based on variables of maternal
age, gestational age at study entry, number
of cigarettes smoked per day, health insur-
ance (public or private) and use of metha-
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done maintenance
Allocation concealment (selection bias) Low risk Computerised allocation.
Blinding (performance bias and detection
bias)
Women and clinical staff
Low risk Placebo-controlled trial with placebo and
treatment packaged in same blister packets
Incomplete outcome data (attrition bias)
All outcomes
Low risk Perinatal outcomes for 95% control group
and 97% intervention group (excluding 1
from each group who withdrew consent
and others lost to follow-up).
Smoking outcomes/participation at end of
pregnancy for 64% control group and 78%
intervention group
All participants with missing data counted
as smokers in this analysis
Selective reporting (reporting bias) Low risk All adverse events reported.
Detection bias (biochemical validation of
smoking outcomes)
Low risk Urine anabasine/anatabine alkaloids from
tobacco which are not altered by NRT
Overall assessment of bias risk Low risk At lower risk of bias.
Pollak 2007
Methods Non-placebo parallel-design RCT.
Participants 181 healthy, US English-speaking women between 13 and 25 weeks pregnant, smoking
>= 5 cigarettes daily and aged >=18 years. Must have smoked > 100 cigarettes in lifetime
Interventions Control group: 5 face-to-face and 1 telephone behavioural counselling sessions with
booklet and support materials.
Intervention group: counselling as above but with additional focus on use of NRT.
Women permitted choice of NRT from patch, gum or lozenge. Patch dose depended
on CPD: < 10 CPD, 7 mg/16 hr, 10 to 14 CPD 14 mg/16 hr and >= 15 CPD 21 mg/
16 hr. Where gum or lozenge used, one 2 mg piece was used for each cigarette smoked
daily. Maximum of 6 weeks NRT provided and no NRT provided when women return
to smoking
Outcomes Self-reported 7-day point prevalence abstinence at 38 weeks.
Also follow-up at 7 weeks after randomisation and 3 months postpartum using self-
report data
Saliva samples for cotinine validation were collected at the intervention session that
coincided with each telephone survey from all women regardless of smoking status. Cut
point for primary outcome <= 10 ng/mL. Validation data were collected at all 3 time
points but is only reported for the 2 data collection points within pregnancy
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Notes Choices of NRT: 72/122 patch = 59%, 32/122 gum = 26.2% and 12/122 lozenge = 9.
8%. 19 women chose another formulation as they could not quit with initial selection
(changes not recorded)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random number generation.
Allocation concealment (selection bias) Low risk Staff responsible for randomising participants used
handheld computer devices which kept allocation
sequence from them until the point of delivering
interventions
Blinding (performance bias and detection
bias)
Women and clinical staff
High risk No placebo used - an open-label trial. Assessors
blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up low for perinatal outcomes (10/
181 births) but more than 30% attrition for assess-
ment of smoking status at the postnatal follow-up
Women lost to follow-up were included as contin-
uing smokers in this analysis
Selective reporting (reporting bias) Low risk All adverse outcomes reported.
Detection bias (biochemical validation of
smoking outcomes)
Low risk Biochemical validation using salivary cotinine.
Overall assessment of bias risk High risk At higher risk of bias.
Stotts 2015
Methods Placebo-controlled, RCT with parallel group design.
Participants Pregnant women who were at least 18 years old; 14-26 weeks’ gestation and currently
smoking at least 1 daily cigarette. Wome were excluded if they had abnormal LFTs;
history of or current seizure disorder or closed head injury with loss of consciousness;
hypersensitivity to bupropion; any psychiatric disorder requiring psychotropic medica-
tion; current anorexia or bulimia; MAO use in the past 2 weeks; major depression or risk
of suicide; illicit substance use in the past 30 days; > 1 alcoholic drink/week; unstable
medical problems; multiple pregnancy; fetal structural anomaly; planned birth at a non-
affiliated hospital; communication problems or lack of transport/phone or current use
of NRT, bupropion or varenicline
37Pharmacological interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stotts 2015 (Continued)
Interventions Bupropion, SR or matching placebo; Bupropion SR was dosed at 150 mg/day for the
first 3 days and 300 mg/d thereafter (150 mg twice a day). Placebo appearance, taste,
and dosing instructions were identical. Patients and providers were masked to treatment
group. Both the groups received 4, weekly, 15-minute smoking cessation counselling
sessions based on Clinical Practice Guidelines delivered by a research nurse
Outcomes The primary smoking outcome was self-reported total abstinence in the prior 7 days (7-
day point prevalence) with saliva cotinine validation at the EOT. Saliva cotinine assays
used a cut point of > 20 ng/mL indicating regular smoking. Exhaled CO concentration
in ppm was measured at each assessment time point using the EC-50 (Vitalograph, Inc.,
Lenexa, KS), to indicate recent exposure to tobacco smoke in ppm. Maternal, perinatal,
and neonatal outcomes assessed included intrauterine fetal death, spontaneous abortion,
placental abruption, preterm birth (< 37 weeks, 0 days), pre-eclampsia, maternal weight
gain, birthweight, umbilical artery pH, gestational age at delivery, fetal growth restric-
tion (birthweight < 10th percentile), neonatal intensive care unit admission, respiratory
complications (per physician notes)
Notes The cut point for saliva cotinine is higher than the current standard
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using permuted block
design.
Allocation concealment (selection bias) Unclear risk There is no description of how randomisa-
tion was operationalised, so this is not clear
Blinding (performance bias and detection
bias)
Women and clinical staff
Low risk As this trial uses visually identical place-
bos, participants and those delivering the
intervention were blind to treatment. It is
not explicitly stated that the assessor of out-
comeswas blinded, but this is likely to be an
omission as with placebo control and ran-
domisation, it seems unlikely that the as-
sessor would not be blinded. Consequently,
the risk of bias has been assessed as ’low’
Incomplete outcome data (attrition bias)
All outcomes
Low risk It is not specifically reported that an inten-
tion-to-treat analysis was used (this would
effectively mean that there was no loss of
data); however at the main outcome point
for smoking cessation, outcome data on
all 11 participants are reported within the
groups to which these were randomised
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Selective reporting (reporting bias) High risk A number of outcomes mentioned in study
methods but are not reported in the results
section
Detection bias (biochemical validation of
smoking outcomes)
Low risk There are validated data presented from
cessation outcomes and although this uses
a high cut point (20 ng/mL for saliva), indi-
vidual participant saliva cotinine readings
are reported and these could be used to eval-
uate findings against a lower cut point, if
desired
Overall assessment of bias risk Unclear risk This has been allocated an unclear risk of
bias; for smoking cessation outcomes, is-
sues highlighted may be problems with de-
scription rather than design or conduct of
the trial
Wisborg 2000
Methods Parallel-design RCT with active and placebo patches and clinicians/researchers and par-
ticipants unaware of allocation
Participants 250 healthy Danish women < 22 weeks pregnant and smoking >= 10 cigarettes daily
Interventions 11 week course of NRT or identical placebo patches: 15 mg/16 hr for 8 weeks then 10
mg/16 hr for 3 weeks plus behavioural counselling and information pamphlet
Intervention = active patch, control = placebo.
Outcomes Self-reported abstinence of >= 7 days at 2nd , 3rd and 4th prenatal visits (4 weeks prior
to delivery).
Follow-ups at times above and also by telephone at 3 months and 1 year after delivery
Notes Saliva cotinine level < 26 ng/mL at the 4th visit (4 weeks prior to expected delivery date)
used to validate reported smoking cessation. The test used could not detect lower than
20 ng/mL (data verified by communication with author). Only self-report data were
collected after childbirth
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised list in balanced blocks.
Allocation concealment (selection bias) Low risk Placebo-controlled trial with allocation
coded until the end of data collection
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Blinding (performance bias and detection
bias)
Women and clinical staff
Low risk Placebo-controlled trial with allocation
coded until the end of data collection
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The treatment allocation of 7 miscarriages
could not be determined. Small loss to fol-
low-up but missing data treated as contin-
uing smokers in this analysis
Selective reporting (reporting bias) Low risk Adverse outcomes reported.
Detection bias (biochemical validation of
smoking outcomes)
Unclear risk Used cut point which is higher than cur-
rently accepted and biochemical test which
could not detect levels of cotinine of < 20
ng/mL (data obtained from authors). Some
respondents reporting smoking cessation
may have actually been still smoking and
the biochemical test would not detect this.
In analyses we dealt with this by using self-
report data in primary analyses and inves-
tigating the impact of using biochemically
validated data in a sensitivity analysis
Overall assessment of bias risk Low risk At lower risk of bias.
CO: carbon monoxide
CPD: cigarettes per day
hr(s): hour(s)
LFTs: liver function tests
mg: milligrams
mg/hr: milligrams per hour
Monoamine oxidase min(s): minute(s)
ng/mL: nanograms per millilitre
NRT: nicotine replacement therapy
ppm: parts per million
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Eades 2012 This was a pilot trial of a smoking cessation intervention developed specially for Aboriginal and Torres Strait Islander
women. It was quasi-randomised as women were allocated to intervention or control in ’control’ or ’intervention’
weeks with the nature of individual weeks determined by random allocation (but outcomes being monitored at the
level of individual women). It was not judged possible to attribute treatment effects in the intervention arm to NRT
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(Continued)
because NRTwas offered as part of a multi-modal intervention which offeredmore behavioural support (in addition
to the NRT) to participants in the intervention group. Additionally, NRT was only offered to those intervention
group women who made 2 failed quit attempts after receiving behavioural components of the intervention and,
in the presentation of outcomes from the study, women who accepted the offer of NRT at this stage could not be
differentiated from other intervention group women. Components of the intervention delivered in addition to the
offer of NRT detailed above were:
i) the use of a ’buddy’ to provide ’lay’ support for women trying to quit,
ii) signing a ’partnership agreement’ with health professionals as evidence of commitment to try quitting,
iii) a high intensity behavioural intervention in early pregnancy and ongoing support
Hegaard 2003 Quasi-random allocation/sequence generation of participants (by their birth dates)
Also, it was not judged possible to attribute treatment effects in the intervention arm to NRT because:
NRT was offered as part of a multi-modal intervention which differed between trial arms, with the intervention
group receiving counselling by specially trained staff on “intervention days” and the control group receiving only
routine advice from their usual midwife
At randomisation, participants did not have to agree to use NRT; of 327 women randomised to the intervention
group only 75 accepted and offer of NRT. Smoking outcomes were not reported within the subgroup of those using
NRT so it was not clear if NRT was responsible for smoking outcomes. Also this post-randomisation self-selection
of participants for NRT use introduces unknown biases into the study. This is not the same as other trials in which
all participants agreed to use and were randomised to potentially receiving NRT
Oncken 2009a This was not an RCT but was a cohort study in which the impacts of nicotine patches or nasal spray on nicotine
exposure in pregnant women were investigated. It was excluded at the stage of abstract scrutiny
NRT: nicotine replacement therapy
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Hankins 2011
Trial name or title Bupropion for smoking cessation during pregnancy
Methods Placebo-randomised, double-blind, controlled trial.
Participants Pregnant women aged 18 and over who are smoked at least 10 daily cigarettes prior to pregnancy (and in
pregnancy smoke at least 5 daily cigarettes) and who are between 13 and 26 weeks’ gestation
Interventions Bupropion (slow release) 150 mg twice daily (after gradual build up in dose) for 12 weeks, dispensed for 30
days at a time
Outcomes Primary outcome: change in withdrawal symptoms from the quit date (onset of smoking cessation + after 1
week of treatment) to that at the completion of study therapy (status post 12 weeks of study treatment, 11
weeks post quit date) measured by Minnesota Nicotine Withdrawal Scale. Other outcomes include: 7-day
point prevalence of smoking abstinence as 3 weeks after a quit date and 7-day point prevalence of smoking
abstinence at 36 to 38 weeks’ gestation
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Hankins 2011 (Continued)
Starting date July 2011.
Contact information mlzimmer@utmb.edu or jbrando@utmb.edu
Notes Aims to recruit 150 participants and to be completed by October 2015
Koren 2008
Trial name or title Study of nicotine replacement therapy in pregnancy
Methods Randomised, controlled open-label study.
Participants • Women who smoke.
• Pregnant women after 12 weeks’ gestation, confirmed by ultrasound.
• On the day of the recruitment, women will be at least 18 years old and no older than 40 years old.
Interventions NRT (Nicoderm patches) at doses of 14 mg/day or 21 mg/day.
Outcomes Smoking cessation.
Starting date August 2008.
Contact information gideon.koren@sickkids.ca
Notes This study has been withdrawn due to recruitment difficulties. I have left it here so readers have an audit trail
for study outcomes
Kranzler 2014
Trial name or title Placebo-controlled trial of Bupropion for smoking cessation in pregnant women (BIBS)
Methods Placebo-randomised, parallel-group, controlled trial.
Participants Pregnant at 13-24 weeks’ gestation and > 18 years of age; currently smoking at least 5 cigarettes per day for the
preceding 7 days and want to quit smoking; able to speak and read English at a 6th grade level or higher, using
the Slosson Oral Reading Test (SORT); committed to remaining in the geographic area for at least 3 months
postpartum; able to sign written informed consent and commit to completing the procedures involved in the
study
Interventions Bupropion 150 mg twice daily for 10 weeks or a visually identical placebo
Outcomes 7-day point prevalence abstinence from smoking; number of cigarettes smoked; frequency of moderate or
severe side effects; birth outcomes; smoking frequency after 10 weeks treatment phase
Starting date Oct 2014.
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Kranzler 2014 (Continued)
Contact information Henry Kranzler, M.D., University of Pennsylvania
timpond@mail.med.upenn.edu
Notes
Oncken 2009c
Trial name or title Pilot study of nicotine replacement for smoking cessation during pregnancy
Methods Open-label, single group cohort study (non-randomised).
Participants Healthy women 13-26 weeks pregnant, smoking 5 daily cigarettes in previous 7 days
Interventions Nicotrol inhaler with behavioural counselling. Inhaler intended to be used for 4 weeks
Outcomes Abstinence from smoking at 2 and 4 weeks after quit date.
Starting date April 27 2009.
Contact information oncken@nso2.uchc.edu
Notes Estimated closing date was November 2010; still listed on clinicaltrials.gov but of “unknown” status as no
data uploaded for over 2 years
Oncken 2012
Trial name or title Nicotine replacement for smoking cessation during pregnancy
Methods Placebo-randomised, double-blind, controlled trial.
Participants Pregnant women aged 16 years or over; 13-26 weeks’ gestation; smoke at least 5 daily cigarettes in previous
7 days and report a previous attempt to stop smoking during this pregnancy
Interventions Nicotrol Inhaler; using up to 2 cartridges per day, for 6 weeks with a 6 week taper
Outcomes 7-day point prevalence of smoking cessation at 32-34 weeks’ gestation
Starting date December 2010.
Contact information Sheila D Thurlowthurlow@uchc.edu
Notes Aims to recruit 360 participants and to be completed by November 2015
NRT: nicotine replacement therapy
ng/mL: nanograms per millilitre
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mg/day:milligrams per day
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D A T A A N D A N A L Y S E S
Comparison 1. Nicotine replacement therapy versus control (Primary outcome - efficacy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Validated cessation in later
pregnancy
8 2199 Risk Ratio (M-H, Random, 95% CI) 1.41 [1.03, 1.93]
1.1 Placebo-controlled trials 5 1926 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.99, 1.66]
1.2 Non placebo-controlled
trials
3 273 Risk Ratio (M-H, Random, 95% CI) 8.51 [2.05, 35.28]
2 Self-report cessation at 3 or 6
months after childbirth
3 625 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.84, 1.77]
2.1 Placebo-controlled trials 2 444 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.75, 1.77]
2.2 Non placebo-controlled
trials
1 181 Risk Ratio (M-H, Random, 95% CI) 1.45 [0.69, 3.03]
3 Self-report cessation at 12
months after childbirth
1 246 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.57, 1.88]
Comparison 2. Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Miscarriage and spontaneous
abortion
4 1782 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.45, 4.77]
2 Stillbirth 4 1777 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.54, 2.84]
3 Mean birthweight (g) 6 2068 Mean Difference (IV, Random, 95% CI) 100.54 [-20.84, 221.
91]
3.1 Placebo-controlled trials 4 1852 Mean Difference (IV, Random, 95% CI) 124.63 [-22.21, 271.
47]
3.2 Non-placebo controlled
trials
2 216 Mean Difference (IV, Random, 95% CI) 36.39 [-256.19, 328.
98]
4 Low birthweight (< 2500 g) 6 2037 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.41, 1.34]
4.1 Placebo-controlled trials 4 1821 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.27, 1.26]
4.2 Non-placebo controlled
trials
2 216 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.61, 2.98]
5 Preterm birth (birth < 37 weeks) 6 2048 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.67, 1.14]
5.1 Placebo-controlled trials 4 1821 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.60, 1.11]
5.2 Non-placebo controlled
trials
2 227 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.62, 2.35]
6 Neonatal intensive care unit
admissions
4 1756 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.64, 1.27]
7 Neonatal death 4 1746 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.17, 2.62]
8 Congenital abnormalities 2 1401 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.36, 1.48]
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9 Caesarean section 2 1401 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.83, 1.69]
Analysis 1.1. Comparison 1 Nicotine replacement therapy versus control (Primary outcome - efficacy),
Outcome 1 Validated cessation in later pregnancy.
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 1 Nicotine replacement therapy versus control (Primary outcome - efficacy)
Outcome: 1 Validated cessation in later pregnancy
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Placebo-controlled trials
Oncken 2008 18/100 14/94 18.1 % 1.21 [ 0.64, 2.29 ]
Coleman 2012 49/521 40/529 33.5 % 1.24 [ 0.83, 1.86 ]
Berlin 2014 25/203 19/199 21.8 % 1.29 [ 0.73, 2.27 ]
Wisborg 2000 22/124 17/126 20.8 % 1.31 [ 0.73, 2.35 ]
Kapur 2001 4/17 0/13 1.2 % 7.00 [ 0.41, 119.46 ]
Subtotal (95% CI) 965 961 95.3 % 1.28 [ 0.99, 1.66 ]
Total events: 118 (NRT), 90 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.45, df = 4 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
2 Non placebo-controlled trials
Hotham 2006 3/20 0/20 1.1 % 7.00 [ 0.38, 127.32 ]
Pollak 2007 17/122 1/59 2.4 % 8.22 [ 1.12, 60.31 ]
El-Mohandes 2013 5/26 0/26 1.2 % 11.00 [ 0.64, 189.31 ]
Subtotal (95% CI) 168 105 4.7 % 8.51 [ 2.05, 35.28 ]
Total events: 25 (NRT), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0032)
Total (95% CI) 1133 1066 100.0 % 1.41 [ 1.03, 1.93 ]
Total events: 143 (NRT), 91 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.51, df = 7 (P = 0.29); I2 =18%
Test for overall effect: Z = 2.15 (P = 0.031)
Test for subgroup differences: Chi2 = 6.59, df = 1 (P = 0.01), I2 =85%
0.1 0.2 0.5 1 2 5 10
Favours control Favours NRT
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Analysis 1.2. Comparison 1 Nicotine replacement therapy versus control (Primary outcome - efficacy),
Outcome 2 Self-report cessation at 3 or 6 months after childbirth.
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 1 Nicotine replacement therapy versus control (Primary outcome - efficacy)
Outcome: 2 Self-report cessation at 3 or 6 months after childbirth
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Placebo-controlled trials
Oncken 2008 11/100 9/94 19.9 % 1.15 [ 0.50, 2.65 ]
Wisborg 2000 26/124 23/126 54.7 % 1.15 [ 0.69, 1.90 ]
Subtotal (95% CI) 224 220 74.5 % 1.15 [ 0.75, 1.77 ]
Total events: 37 (NRT), 32 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Non placebo-controlled trials
Pollak 2007 24/122 8/59 25.5 % 1.45 [ 0.69, 3.03 ]
Subtotal (95% CI) 122 59 25.5 % 1.45 [ 0.69, 3.03 ]
Total events: 24 (NRT), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 346 279 100.0 % 1.22 [ 0.84, 1.77 ]
Total events: 61 (NRT), 40 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
0.5 0.7 1 1.5 2
Favours control Favours NRT
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Analysis 1.3. Comparison 1 Nicotine replacement therapy versus control (Primary outcome - efficacy),
Outcome 3 Self-report cessation at 12 months after childbirth.
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 1 Nicotine replacement therapy versus control (Primary outcome - efficacy)
Outcome: 3 Self-report cessation at 12 months after childbirth
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wisborg 2000 19/124 18/122 100.0 % 1.04 [ 0.57, 1.88 ]
Total (95% CI) 124 122 100.0 % 1.04 [ 0.57, 1.88 ]
Total events: 19 (NRT), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours NRT
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Analysis 2.1. Comparison 2 Nicotine replacement therapy versus control (Secondary outcomes - safety),
Outcome 1 Miscarriage and spontaneous abortion.
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 2 Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome: 1 Miscarriage and spontaneous abortion
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berlin 2014 1/189 1/188 18.2 % 0.99 [ 0.06, 15.79 ]
Coleman 2012 3/515 2/521 43.6 % 1.52 [ 0.25, 9.04 ]
Oncken 2008 2/100 1/91 24.5 % 1.82 [ 0.17, 19.74 ]
Pollak 2007 1/119 0/59 13.7 % 1.50 [ 0.06, 36.27 ]
Total (95% CI) 923 859 100.0 % 1.47 [ 0.45, 4.77 ]
Total events: 7 (NRT), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours NRT Favours control
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Analysis 2.2. Comparison 2 Nicotine replacement therapy versus control (Secondary outcomes - safety),
Outcome 2 Stillbirth.
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 2 Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome: 2 Stillbirth
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berlin 2014 5/189 6/188 50.2 % 0.83 [ 0.26, 2.67 ]
Coleman 2012 5/512 2/519 25.7 % 2.53 [ 0.49, 13.00 ]
Oncken 2008 2/100 1/91 12.1 % 1.82 [ 0.17, 19.74 ]
Pollak 2007 2/119 1/59 12.1 % 0.99 [ 0.09, 10.72 ]
Total (95% CI) 920 857 100.0 % 1.24 [ 0.54, 2.84 ]
Total events: 14 (NRT), 10 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NRT Favours control
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Analysis 2.3. Comparison 2 Nicotine replacement therapy versus control (Secondary outcomes - safety),
Outcome 3 Mean birthweight (g).
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 2 Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome: 3 Mean birthweight (g)
Study or subgroup NRT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Placebo-controlled trials
Berlin 2014 189 3078 (648) 188 3024 (582) 19.5 % 54.00 [ -70.32, 178.32 ]
Coleman 2012 521 3180 (610) 521 3200 (590) 22.5 % -20.00 [ -92.87, 52.87 ]
Oncken 2008 93 3287 (566) 90 2950 (653) 16.1 % 337.00 [ 159.71, 514.29 ]
Wisborg 2000 124 3457 (605) 126 3271 (605) 17.9 % 186.00 [ 36.00, 336.00 ]
Subtotal (95% CI) 927 925 76.0 % 124.63 [ -22.21, 271.47 ]
Heterogeneity: Tau2 = 17868.57; Chi2 = 16.71, df = 3 (P = 0.00081); I2 =82%
Test for overall effect: Z = 1.66 (P = 0.096)
2 Non-placebo controlled trials
El-Mohandes 2013 25 3203 (588) 25 2997 (482) 9.9 % 206.00 [ -92.04, 504.04 ]
Pollak 2007 109 3053 (681) 57 3148 (648) 14.1 % -95.00 [ -306.29, 116.29 ]
Subtotal (95% CI) 134 82 24.0 % 36.39 [ -256.19, 328.98 ]
Heterogeneity: Tau2 = 27928.43; Chi2 = 2.61, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 1061 1007 100.0 % 100.54 [ -20.84, 221.91 ]
Heterogeneity: Tau2 = 15624.49; Chi2 = 19.63, df = 5 (P = 0.001); I2 =75%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
-200 -100 0 100 200
Favours control Favours NRT
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Analysis 2.4. Comparison 2 Nicotine replacement therapy versus control (Secondary outcomes - safety),
Outcome 4 Low birthweight (< 2500 g).
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 2 Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome: 4 Low birthweight (< 2500 g)
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Placebo-controlled trials
Berlin 2014 25/189 33/188 23.4 % 0.75 [ 0.47, 1.22 ]
Coleman 2012 56/507 43/517 24.8 % 1.33 [ 0.91, 1.94 ]
Oncken 2008 2/93 16/85 10.5 % 0.11 [ 0.03, 0.48 ]
Wisborg 2000 4/120 11/122 14.0 % 0.37 [ 0.12, 1.13 ]
Subtotal (95% CI) 909 912 72.7 % 0.58 [ 0.27, 1.26 ]
Total events: 87 (NRT), 103 (Control)
Heterogeneity: Tau2 = 0.44; Chi2 = 15.22, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Non-placebo controlled trials
El-Mohandes 2013 3/25 4/25 11.0 % 0.75 [ 0.19, 3.01 ]
Pollak 2007 17/109 5/57 16.3 % 1.78 [ 0.69, 4.57 ]
Subtotal (95% CI) 134 82 27.3 % 1.35 [ 0.61, 2.98 ]
Total events: 20 (NRT), 9 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.75 (P = 0.46)
Total (95% CI) 1043 994 100.0 % 0.74 [ 0.41, 1.34 ]
Total events: 107 (NRT), 112 (Control)
Heterogeneity: Tau2 = 0.33; Chi2 = 17.02, df = 5 (P = 0.004); I2 =71%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 2.23, df = 1 (P = 0.13), I2 =55%
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Analysis 2.5. Comparison 2 Nicotine replacement therapy versus control (Secondary outcomes - safety),
Outcome 5 Preterm birth (birth < 37 weeks).
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 2 Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome: 5 Preterm birth (birth < 37 weeks)
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Placebo-controlled trials
Berlin 2014 19/189 20/188 20.1 % 0.94 [ 0.52, 1.71 ]
Coleman 2012 40/507 45/517 42.8 % 0.91 [ 0.60, 1.36 ]
Oncken 2008 7/93 16/85 10.1 % 0.40 [ 0.17, 0.92 ]
Wisborg 2000 10/120 12/122 11.1 % 0.85 [ 0.38, 1.89 ]
Subtotal (95% CI) 909 912 84.1 % 0.81 [ 0.60, 1.11 ]
Total events: 76 (NRT), 93 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.28, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.29 (P = 0.20)
2 Non-placebo controlled trials
El-Mohandes 2013 1/25 2/25 1.3 % 0.50 [ 0.05, 5.17 ]
Pollak 2007 24/119 9/58 14.6 % 1.30 [ 0.65, 2.61 ]
Subtotal (95% CI) 144 83 15.9 % 1.20 [ 0.62, 2.35 ]
Total events: 25 (NRT), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 1053 995 100.0 % 0.87 [ 0.67, 1.14 ]
Total events: 101 (NRT), 104 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.91, df = 5 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 1.06, df = 1 (P = 0.30), I2 =6%
0.01 0.1 1 10 100
Favours NRT Favours control
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Analysis 2.6. Comparison 2 Nicotine replacement therapy versus control (Secondary outcomes - safety),
Outcome 6 Neonatal intensive care unit admissions.
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 2 Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome: 6 Neonatal intensive care unit admissions
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berlin 2014 10/189 13/188 18.6 % 0.77 [ 0.34, 1.70 ]
Coleman 2012 33/507 35/517 56.4 % 0.96 [ 0.61, 1.52 ]
Oncken 2008 7/93 11/85 14.7 % 0.58 [ 0.24, 1.43 ]
Pollak 2007 13/119 4/58 10.3 % 1.58 [ 0.54, 4.64 ]
Total (95% CI) 908 848 100.0 % 0.90 [ 0.64, 1.27 ]
Total events: 63 (NRT), 63 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.20, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 2.7. Comparison 2 Nicotine replacement therapy versus control (Secondary outcomes - safety),
Outcome 7 Neonatal death.
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 2 Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome: 7 Neonatal death
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berlin 2014 2/189 0/188 20.7 % 4.97 [ 0.24, 102.91 ]
Coleman 2012 0/507 2/517 20.7 % 0.20 [ 0.01, 4.24 ]
Oncken 2008 1/93 2/85 33.5 % 0.46 [ 0.04, 4.95 ]
Pollak 2007 1/109 1/58 25.1 % 0.53 [ 0.03, 8.35 ]
Total (95% CI) 898 848 100.0 % 0.66 [ 0.17, 2.62 ]
Total events: 4 (NRT), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.42, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Nicotine replacement therapy versus control (Secondary outcomes - safety),
Outcome 8 Congenital abnormalities.
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 2 Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome: 8 Congenital abnormalities
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berlin 2014 4/189 5/188 29.5 % 0.80 [ 0.22, 2.92 ]
Coleman 2012 9/507 13/517 70.5 % 0.71 [ 0.30, 1.64 ]
Total (95% CI) 696 705 100.0 % 0.73 [ 0.36, 1.48 ]
Total events: 13 (NRT), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NRT Favours Control
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Analysis 2.9. Comparison 2 Nicotine replacement therapy versus control (Secondary outcomes - safety),
Outcome 9 Caesarean section.
Review: Pharmacological interventions for promoting smoking cessation during pregnancy
Comparison: 2 Nicotine replacement therapy versus control (Secondary outcomes - safety)
Outcome: 9 Caesarean section
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berlin 2014 28/189 30/188 36.0 % 0.93 [ 0.58, 1.49 ]
Coleman 2012 105/507 79/517 64.0 % 1.36 [ 1.04, 1.77 ]
Total (95% CI) 696 705 100.0 % 1.18 [ 0.83, 1.69 ]
Total events: 133 (NRT), 109 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.87, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NRT Favours control
A D D I T I O N A L T A B L E S
Table 1. Distribution of twin births and fetal losses within singleton pregnancies in NRT and control groups
Twin pregnan-
cies, n
Miscarriage, n Stillbirth, n Termination, n Miss-
ing data: birth
outcomes/
whether
birth occurred
not known
Non-viable
pregnancy
at randomisa-
tion, n
Known live
births
from singleton
pregnancies, n
NRT Con-
trol
NRT Con-
trol
NRT Con-
trol
NRT Con-
trol
NRT Con-
trol
NRT Con-
trol
NRT Con-
trol
Wis-
borg
2000
1∗ 7∗ 120 122
Pollak
2007
2 0 1 0 2 1 0 0 8 1 1 0 109 57
On-
cken
2008
Women with
multiple
births were ex-
2 1 2 1 0 3∗∗ 3 4 0 0 93 85
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Table 1. Distribution of twin births and fetal losses within singleton pregnancies in NRT and control groups (Continued)
cluded
Cole-
man
2012
4 8 3 2 5 2 1 0 4 10 1 0 503 507
Berlin
2014
3 4 1 1 4 5 1*** 1*** 3 0 0 0
189****
188
El-
Mo-
han-
des
2013
0 0 0 0 0 0 0 0 1 1 0 0 25 25
* the treatment allocation of the twin pregnancy and miscarriages are not known
** authors confirmed that all terminations were done for social reasons and fetus thought to be normal
*** done for medical problems judged incompatible with birth survival
**** includes 2 infants who died during childbirth
Table 2. Adherence with nicotine replacement therapy regimens
Study Adherence with offered regimen as a percentage of
complete course
Adherence with offered regimen in terms of period of
use
Wisborg 2000 Complete adherence with 11 weeks course: nicotine
group = 11%, placebo = 7%. Partial adherence (up to 8
weeks use): nicotine group = 17%, placebo = 8%
Median number patches (ranges): nicotine group = 14
(0-77) - median = approximately 2 weeks, placebo = 7
(0-77) - median approximately 1 week
Kapur 2001 In the nicotine group, 4/17 (23.5%) completed the 14-
week programme. In the placebo group, no participants
completed the programme
In the nicotine group, 4/17 (23.5%) completed the 14-
week programme, 3/17 (17.6%) - used patch for at least
3 weeks and 10/17 (58.8%) - used patch for less than 1
week
In the placebo group, no participants completed the pro-
gramme, 3/13 (23%) used patch for between 4 and 5
weeks and 10/13 (76.9%) used patch for < 1 week
Hotham 2006 25% (5) participants complied fully with protocol: ‘con-
tinuous patch use till 12 weeks or confident that abstinence
achieved or adverse reaction experienced’.
50% (10) of participants used NRT for 6 or less weeks.
Pollak 2007 Difficult to ascertain from this manuscript. A secondary
publication reported that 29% of participants usedNRT
as directed for intended 6-week programme (Fish 2009)
.
Means of reported periods of use:
Patch = 23.4 patches = 3.3 weeks
Gum = 8 days
Lozenge = 4 days
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Table 2. Adherence with nicotine replacement therapy regimens (Continued)
Oncken 2008 Not clearly reported. The nicotine group used gum for a mean (standard de-
viation) of 37.8 (3.8) days (i.e. just > 5 weeks). The
placebo group reported using gum for a mean (standard
deviation) of 29.9 (3.4) days (i.e. just > 4 weeks)
Coleman 2012 Limited compliance with the intervention. Only 7.2%
of women (35 of 485) assigned to receive NRT and 2.
8% (14 of 496) assigned to receive placebo reported us-
ing trial medications for more than 1 month (2 months
represented a complete course); rates of use of non-study
nicotine-replacement therapywere very low.Most partic-
ipants had no additional contact, either face-to-face or by
text message, with smoking-cessation advisors; among
those who did, the frequency of contact was similar in
the 2 groups
Most participants discontinued patches after only short
usage periods: in the nicotine group 60.1% of partici-
pants used patches for no longer than 2 weeks and in the
placebo patch group this figure was 76.8%
Berlin 2014 In contrast to other studies, women were issued with a
much longer course of transdermal patches; these were
issued from women’s quit dates to their delivery
Compliance was measured using self-reported data on
patches used between study visits and was obtained at
1016 study visits from 307 (76%) participants; 164
(84%) in NRT and 143 (72%) in placebo groups
Median (IQR) reported patch use in NRT group was
85% (56% to 99%) and 83% (56% to 95%) in placebo.
However, it is not clear how these figures relate to the rate
with which participants discontinued the intervention.
Overall, 225 (60.0%) of participants stopped using trial
treatments; 105 (51.7%) in the NRT group and 60.3%
in placebo
This was not reported but has less meaning for this RCT
as women started using patches at different points in
pregnancy and continued until childbirth
IQR: interquartile range
NRT: nicotine replacement therapy
RCT: randomised controlled trial
WH A T ’ S N E W
Last assessed as up-to-date: 11 July 2015.
Date Event Description
11 July 2015 New search has been performed Search updated. Three new trials included in this update
(Berlin 2014; El-Mohandes 2013; Stotts 2015).
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(Continued)
11 July 2015 New citation required but conclusions have not changed Review updated.
This update looked for both trials of pharmacothera-
pies and also of Electronic Nicotine Delivery Systems
(ENDS) used for smoking cessation in pregnancy; it
found mainly nicotine replacement therapy (NRT) trials
with one bupropion trial which randomised only 11 preg-
nant smokers. A total of nine trials are included in this
update
The conclusions are largely the same, although there is
now more evidence to suggest that NRT used in preg-
nancy increases smoking cessation rates measured in late
pregnancy by approximately 40%. There is evidence, sug-
gesting that when potentially-biased, non-placebo RCTs
are excluded from analyses, NRT is nomore effective than
placebo
C O N T R I B U T I O N S O F A U T H O R S
Review authors Tim Coleman (TC) and Catherine Chamberlain (CC) independently inspected search results and selected papers for
inclusion in the review with disagreements resolved by discussion with Sue Cooper (SC). Jo Leonardi-Bee (JLB) extracted data from
three papers, TC from two (excluding one authored by him, from which CC extracted data) and Mary-Ann Davey (MD), from one.
Discussion with SC was used to resolve disagreements. TC contacted study authors as appropriate and he also entered data into Revman
software. TC and SC assessed the risk of bias for two studies and the third (authored by SC and TC) was assessed by JLB and CC. All
authors commented on the final draft of the updated review after TC had produced an initial draft and TC finalised the text.
D E C L A R A T I O N S O F I N T E R E S T
Within the last five years, Tim Coleman has once been paid for speaking at two meetings arranged by Pierre Fabre Laboratories
(manufacturers of nicotine replacement therapy). Tim Coleman was Chief Investigator and Sue Cooper Trial Manager for a UK-based,
placebo-randomised controlled trial of NRT in pregnancy which was funded by public monies and used nicotine replacement products
which are not available on prescription or ’over the counter’ in any country (Coleman 2012). This trial is included in this review but
neither Tim nor Sue undertook data extraction from or quality assessment of either paper reporting this study.
Catherine Chamberlain is lead author of the Cochrane review on Psychosocial interventions for supporting women to stop smoking in
pregnancy (Chamberlain 2013); earlier versions of this included a subgroup analysis of trials involving provision of NRT as part their
intervention strategy (Lumley 2009). Catherine works for the Indigenous Health Equity Unit, which receives some funding from
VicHealth, which in turn is partly government funded from tobacco revenue to reduce tobacco harm, and is governed by the Tobacco
Act. CC does not have any other conflicts of interest to declare.
Jo Leonardi-Bee receives an educational grant from Roche which is unrelated to any smoking cessation treatments.
Mary-Ann Davey does not have any conflicts of interest to declare.
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• Victorian Health Promotion Foundation, Australia.
• Department of Health, UK funding for EPI-Centre, London University, UK.
• Public Health Branch Victorian Department of Human Services, Australia.
• (TC, SC and JLB) National Institute for Health Research (NIHR), Programme Grant for Applied Research programme (grant
number RP-PG 0109-10020), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
A protocol for this (pharmacological interventions) review was submitted prior to initiating this work; however, there were two
differences between the protocol and the first version of this review and further minor changes were made for this first review update.
These are described below with explanations of why changes were made.
Types of studies: in the protocol we planned to search for only nicotine replacement therapy (NRT) studies but realised that if studies
using other smoking cessation drugs had been conducted, these should be included. Consequently, for the first version of this review
we altered criteria to potentially include all trials of smoking cessation pharmacotherapies conducted in pregnancy. Additionally, in
the period between publication of the review and the first update, the use of ’e cigarettes’ increased substantially and at least one
smoking cessation trial (non-pregnant smokers) has been published. Consequently, we believed it was important to search for any studies
investigating the use of e-cigarettes (now called Electronic Nicotine Delivery Systems (ENDS)) for smoking cessation in pregnancy
and, if any such studies which met review eligibility criteria were found, to include these in the review update.
Changes to outcomes: this review has slightly different pregnancy and birth outcomes compared to those listed in the protocol.
The differences between the protocol and first version were: miscarriage and spontaneous abortion, stillbirth and neonatal deaths and
caesarean section. At the protocol stage, we had planned to report perinatal death, post-randomisation fetal death and fetal demise, but
as the use of these terms made the review less amenable to comprehension and so these were dropped and replaced with more standard
terms. We also decided to use the term ’adherence’ rather than compliance as this is more appropriate to describe medication taking
and we also realised that, should any trials document the long-term effects of pharmacotherapies, this would be important to document
and this was added as an outcome.
For the update, we have added maternal hypertension, infant respiratory symptoms and infant development to listed, named safety
outcomes that were investigated. This was because more than one trial has now recorded data on hypertension, so there was now
potential for meta-analysis of this outcome and, for the first time, we identified a trial that had monitored infant outcomes after the
perinatal period and these seemed important to include for comprehensiveness.
Clarification of subgroup and sensitivity analyses: the protocol was rather vague regarding subgroup and sensitivity analyses, so
prior to undertaking the review we made these explicit.
The only planned subgroup analysis was: i) a comparison of placebo-randomised controlled trials with trials that did not use a placebo.
The two planned sensitivity analyses were i) including only trials with biochemical validation and ii) excluding those which reported
substantially lower adherence.
For the previous version of the review we took the decision to use self-reported data from Wisborg 2000 in primary analyses and to
report analyses using biochemically-validated data from this study alongside the primary analysis as a sensitivity analysis. This was a
post hoc sensitivity analysis and was not specified in the protocol.
We have now reconsidered this issue and, in retrospect, the decision to use self-report rather than validated data from Wisborg 2000
in primary analyses seems flawed. Possibly, the most important issue to affect ascertainment bias in smoking cessation studies is that
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of participants reporting abstinence when they are in fact still smoking. The converse, in which participants falsely report that they are
smoking is not generally considered likely to occur frequently. Consequently, biochemical validation usually detects some false reports
of abstinence and lower cut points for biochemical tests are likely to detect more of these. A higher than usual cut point will still detect
some false reports of abstinence; in particular, false reports made by participants who are still smoking heavily are more likely to be
detected. This means that even when validation uses a higher than standard cut point, validated rather than self-report data should be
used in primary analyses.
This issue is described in detail in the ‘Blinding (performance and detection bias)’ under the sub-heading ‘Detection bias’.
Given the above, the review now reports a primary ‘efficacy’ analysis using validated data only (all studies provided this) and text has
been altered to reflect this fact. The updated review now includes no post hoc sensitivity analyses.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Tobacco Use Cessation Products; Pregnancy Complications [∗drug therapy]; Pregnancy Outcome; Randomized Controlled Trials as
Topic; Smoking Cessation [∗methods]
MeSH check words
Female; Humans; Pregnancy
62Pharmacological interventions for promoting smoking cessation during pregnancy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
